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ABSTRACT

The discovery of nitric oxide (NO), a toxic gas, as a gasotransmitter produced by
mammalian cells has generated interest in other gases that may act as signaling
molecules. One of those gases is hydrogen sulfide (H2S), produced by the transsulfuration
enzymes CBS and CSE, which has been postulated to be a gasotransmitter like NO. We
developed a microplate-based colourimetric assay for free H2S gas. Solutions of
dissolved H2S spontaneously release gaseous H2S. In our assay gaseous H2S is released
from solution, and reacts with silver embedded on the underside of a microplate cover,
forming Ag2S, which can be quantified by absorbance. Using this assay the kinetic
parameters of CSE were measured, as was H2S production from mouse liver
homogenates. H2S has been postulated to signal through modification of cysteine residues
on proteins (S-sulfuration), and the first protein shown to be S-sulfurated was GAPDH.
We reinvestigated the H2S-induced S-sulfuration of GAPDH, and the effect of the initial
redox state of the enzyme on S-sulfuration. Contrary to the previous literature results, we
found that Cys 156 was S-sulfurated, and not the active site Cys 152. S-sulfuration of Cys
156 caused a decrease in enzymatic activity. It was possible to S-sulfurate Cys 152 in a
C156S mutant of GAPDH, which caused a decrease in enzymatic activity. We propose a
new role for Cys 156 as a protective thiol for Cys 152. Our results also show that
polysulfides, which can be generated from H2S, are a stronger S-sulfurating agent than
NaSH. When analyzing protein modifications by mass spectrometry, the tryptic peptide
of interest may be in low stoichiometry compared to the rest of the digest. This may
necessitate sample enrichment methods. We tested gold nanoparticles (AuNPs) as an
enrichment method for sulfur-containing peptides. AuNPs showed some affinity for
sulfur-containing peptides, and may be used in studies of protein thiols by mass
spectrometry. NO has been shown to be an important mediator of wound healing, and
NO-releasing materials may be used as wound dressings. We started the development of
a chitosan-based NO-releasing wound dressing, which releases NO from nitrite (NO2-) by
copper ions. All major components in our design, chitosan, copper, and NO, have been
previously shown to have therapeutic properties.
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CHAPTER 1

GENERAL INTRODUCTION

1

1.1 Hydrogen Sulfide
1.1.1 Introduction and Biological Functions of H2S
Hydrogen sulfide (H2S) has long been known to be a toxic pollutant produced from
decomposition of organic matter and from various industrial processes. The toxicity of
H2S has been known for over a century, and its toxic effects observed for longer than
that. The production of small amounts of H2S in mammalian tissues has been known for
decades [1], although the physiological implications of this were not explored until the
late 1990’s. The identification of nitric oxide (NO) as the endothelium-derived relaxing
factor (EDRF) in the late 1980’s likely generated additional interest in other gases
produced in the body that may act as signaling molecules [2]. In the late 1990’s and early
2000’s experiments showed alteration in H2S homeostasis affected important
physiological processes [3, 4]. This has led to the postulation that H2S is a physiological
gasotransmitter [4, 5], like NO and CO, which is synthesized at low levels in tissues to
fulfill a signaling function. Since then the interest in H2S research has grown
tremendously, and subsequent studies have revealed effects of H2S in almost every organ
system.
One of the earliest studies on H2S showed exogenous H2S was, similarly to NO,
able to cause vascular smooth muscle relaxation [4]. The mechanism of vascular smooth
muscle relaxation was discovered to be through opening of ATP-sensitive potassium
channels (KATP) [6]; the mechanism was later hypothesized to be S-sulfuration
(sulfhydration) of the KATP channel SUR subunit [7, 8]. Since then H2S has been shown
to act as a vasodilator in many different types of vascular tissues [9-19]. These
experiments generally involve the application of exogenous H2S to isolated blood vessels.
Although KATP channels were hypothesized to be the molecular targets of H2S, other
pathways have been proposed as well, including voltage-gated Ca2+ channels [13], Cl/HCO3- [14, 15], Big Potassium (BKCa) channels [16], potassium voltage-gated channels
(KCNQ) [17], L-type Ca2+ channels and K channels (but not KATP, KCa, KV, or Kir
subtypes) [18], and calcium-activated chloride channels (CaCCs) [19]. The type of blood
vessel as well as the species may determine the exact mechanism of vasorelaxation, and
both endothelium-dependent and endothelium-independent types of vasorelaxation have
2

been observed in the literature [18]. Paradoxically it has also been reported that H2S
causes vasoconstriction [20-22]; this process has been determined to be O2-dependent. At
low O2 concentrations H2S acts as a vasodilator, while at higher than physiological O2
concentrations H2S acts as a vasoconstrictor [20]. It has been hypothesized that H2S acts
as an O2 sensor and controls hypoxic pulmonary vasoconstriction [23, 24], although this
hypothesis has been recently questioned [25]. One of the most widely-cited lines of
evidence is that CSE-knockout mice were found to be hypertensive, displayed a
diminished endothelium-dependent vasorelaxation, and had lower tissue levels of H2S
[26]. This has not been independently verified since an independent study on CSE
knockout mice showed the mice were normotensive [27]. H2S has also been proposed to
be endothelium derived hyperpolarizing factor (EDHF) [8, 28-30]. EDHF is a nitric oxide
synthase and cyclooxygenase independent vascular relaxation pathway [31]. EDHF is
dominant is small blood vessels, while NO is dominant in large ones. Although H2S has
been proposed to be EDHF, many chemical species have been proposed to be the EDHF
including epoxyeicosatrienoic acids, H2O2, K+, and C-type natriuretic peptide [32]. It is
likely EDHF represents a mechanism of smooth muscle hyperpolarization, which can be
initiated by many, and not a single, chemical species.
H2S can affect ion channels and numerous functions of H2S have been postulated
in the nervous system. The two main proposed roles of H2S in the nervous system are
neuromodulation and neuroprotection [33]. One of the first studies on the biological
functions of endogenous H2S by Abe and Kimura in 1996 found that H2S enhances Nmethyl-D-aspartate (NMDA) receptor mediated current and enhances neuronal long term
potentiation [3]. H2S facilitates long term potentiation by increasing Ca2+ uptake in
astrocytes by activation of transient receptor potential cation member A1 (TRPA1)
channels [34, 35]. Astrocytes then release D-serine into the synapse which enhances the
activity of NMDA receptors [36]. Polysulfides were ~300 times more effective at
increasing Ca2+ uptake than H2S [34]. H2S also has the ability to modulate nociception
(pain sensing) [37]. H2S causes hyperalgesia (increased sensitivity to pain) in animal
models by stimulating CaV3.2 T-type Ca2+ channels [38-40] which are present in nerve
endings [41]. The mechanism is due to H2S reacting with endogenous Zn2+ ions which
endogenously inhibit T-type Ca2+ channels [42-44]. H2S also acts as a pro-nociceptor by
3

activating TRPA1, a channel expressed in sensory neurons which responds to
temperature and natural chemical irritants, among other stimuli [45-47].
H2S has been linked to major neurological diseases Alzheimer’s disease, and
Parkinson’s disease. Elevated plasma homocysteine level has been associated with
Alzheimer’s disease [48], suggesting the H2S-producing enzyme CBS, which also
metabolizes homocysteine, is involved in the pathogenesis of the disease [49]. Decreased
levels of H2S have been detected by GC in brain autopsy samples from Alzheimer’s
disease patients [50]. The levels of CBS in Alzheimer’s brain were unchanged, however
the levels of CBS activator S-adenosyl-L-methionine (SAM) were lower, and levels of
homocysteine were higher. NaSH was able to reduce amyloid beta protein levels in SHSY5Y cells by inhibiting the γ-secretase protein [51]. In a rat model of Alzheimer’s
disease treatment with NaSH or spa-water rich with H2S (Tabiano water) improved
learning and memory [52]. The treatment lowered the size of amyloid beta plaques and
increased the amount of healthy neurons. Similarly in a mouse model of Alzheimer’s
disease treatment of NaSH improved spatial learning and memory and lessened plaque
formation [53].
Elevated plasma homocysteine levels have been also associated with severity of
Parkinson’s disease [54, 55], a disease characterized by the loss of dopaminergic neurons
in the brain. NaSH was able to reduce 1-methyl-4-phenylpyridinium ion (MPP+) induced
cytotoxicity and apoptosis in PC12 cells, a cell line commonly used to study Parkinson’s
disease [56]. NaSH was also able to reduce cytotoxicity and apoptosis in SH-SY5Y cells
(a type of human neuroblastoma cell line) treated with rotenone, a pesticide which can
degrade dopaminergic neurons [57], and in SH-SY5Y cells treated with 6hydroxydopamine (6-OHDA), a dopaminergic neurotoxin [58]. Various H2S-releasing LDOPA derivatives have been developed and tested in cell [59], and animal models of
Parkinson’s disease [60]. Inhaled H2S has also been shown to be neuroprotective in a
mouse model of Parkinson’s disease [61]. H2S has also been shown to be neuroprotective
against lipopolysaccharide (LPS) induced inflammation [62], and glutamate toxicity [63,
64].
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Although low concentrations of H2S have been demonstrated to have therapeutic
properties in disease models, it is well-known that H2S is a toxic gas which can be lethal
at higher concentrations. The concentration of H2S is larger determinant of toxicity rather
than the length of exposure [65]. In animal studies using rats, LC50 for 2 h of exposure
was 587 ppm, while LC50 for 6 h of exposure was 335 ppm. The symptoms associated
with H2S toxicity are eye irritation, olfactory paralysis, pulmonary edema, and abrupt loss
of consciousness [66]. Perhaps the most famous symptom of H2S toxicity is olfactory
paralysis. The human nose is extremely sensitive to H2S at low concentrations and can
smell 0.01-0.3 ppm H2S, while at higher concentrations of ~100 ppm H2S causes
olfactory paralysis and the characteristic H2S smell disappears [66]. Olfactory paralysis
occurs due to neurotoxicity of H2S towards olfactory bulb and fibers [67], and a
permanent decrease in the sense of smell has been reported in patients who recovered
from H2S poisoning [68]. Eye and lung irritation can occur at 20-50 ppm H2S, pulmonary
edema at 250-500 ppm, sudden loss of consciousness at 500 ppm and prolonged exposure
at 500 ppm may cause death [66]. The mechanism of H2S toxicity is similar to that of
cyanide; both cyanide and H2S inhibit cellular respiration by inhibiting mitochondrial
cytochrome c oxidase [69]. When exposed to 80 ppm H2S mice exhibit a reduced
metabolic rate and enter a state of suspended animation [70]. In this state core body
temperature dropped to 2 °C above ambient temperature and breathing rate dropped from
120 breaths per minute to 10. When brought out of suspended animation the mice
exhibited no behavioral or functional changes. Similarly oil patch workers who lost
consciousness due to high but transient H2S concentrations experienced rapid recovery
[66].
1.1.2 H2S-Producing Enzymes
H2S may be produced enzymatically by cystathionine β-synthase (CBS), cystathionine γlyase (CSE), or through the collective action of enzymes cysteine aminotransferase
(CAT) and 3-mercaptopyruvate sulfurtransferase (3-MST) [1]. As their names suggest
the enzymes are not exclusively H2S-producing enzymes, and perform other important
functions in addition to H2S production. CBS and CSE are PLP (pyridoxal phosphate)
dependent enzymes involved in the reverse transsulfuration pathway [1]. The reverse
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transsulfuration pathway is responsible for the conversion of homocysteine, which can be
produced from methionine, to cysteine, and as a result cysteine is a non-essential amino
acid for humans [71-73]. CBS catalyzes the first step of the transsulfuration pathway,
which is the formation of cystathionine by linking homocysteine and serine (Figure 1.1.21) [74, 75]. CSE catalyzes the second step of the transsulfuration pathway, which is the
cleavage of cystathionine to form α-ketobutyrate, cysteine, and ammonia (Figure 1.1.21). Due to low substrate specificity CBS and CSE can also catalyze a number of other
reactions where H2S is formed as a byproduct (Figures 1.1.2-2 & 1.1.2-3) [74]. The
second reaction catalyzed by CBS can metabolize homocysteine through a condensation
reaction with cysteine, generating cystathionine and H2S. The third and fourth reactions
catalyzed by CBS are the conversion of cysteine to serine and H2S, and condensation of
cysteine to form lanthionine and H2S. CSE catalyzes the condensation of cysteine to
lanthionine and H2S. CSE can metabolize cysteine to pyruvate, ammonia, and H2S. CSE
catalyzes the condensation of homocysteine to form homolanthionine and H2S. CSE
catalyzes the condensations of cysteine and homocysteine form its transsulfuration
substrate cystathionine and H2S. CSE can also catalyze homocysteine to form αketobutyrate, H2S, and ammonia. The transsulfuration pathway plays an important role in
catabolizing homocysteine [76], which is a toxic metabolite, and maintaining glutathione
redox status by generating cysteine, which can be incorporated into GSH [76, 77].
Lanthionines are also starting to be considered neuroprotective molecules in the nervous
system [76, 78]. CBS and CSE can also use cystine (cysteine disulfide) as a substrate to
produce cysteine persulfides (Cys-SSH) [79, 80]. Cysteine persulfides can react with
reduced glutathione to form glutathione persulfide, and may S-sulfurate proteins.
Cysteine persulfides and glutathione persulfides have also been detected in vivo [79],
although their physiological significance has not yet been explored. In H2S research, the
biological effects due to alterations in CBS and CSE homeostasis are generally
considered to be solely H2S-related.
The human CBS KM value for condensation of serine and homocysteine to form
cystathionine is 2.76 mM [74]. The human CBS KM values for H2S producing reactions;
conversion cysteine to serine, condensation of cysteine to lanthionine, and condensation
of cysteine and homocysteine to cystathionine are 6.8 mM. The human CSE KM value for
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conversion of cystathionine to cysteine is 0.5 mM, while the KM value for H2S generation
from cysteine is 2.75 mM [81]. Cytosol cystathionine and cysteine concentrations are
estimated at 10 µM and 100 µM respectively [74]. The large KM values for CBS and
CSE, compared to substrate concentrations, indicate activity is highly dependent on
substrate concentrations. CSE is more efficient at catalyzing its transsulfuration substrate,
cystathionine, than H2S production from cysteine. The catalytic efficiency (kcat/KM) of
CSE for cystathionine catabolism is 1.5 x 104 M-1 s-1, while the catalytic efficiency of
CSE for H2S production from cysteine is 1.5 x 102 M-1 s-1 [81]. Cysteine is the most
commonly used substrate added to cells or lysates in order to stimulate H2S production.
CBS is a homotetramer, each subunit is 63 kDa [82]. CBS contains a 70 amino
acid length N-terminal heme domain, followed by a PLP-binding site and catalytic core,
and a C-terminal regulatory domain [83]. The catalytic core includes a CXXC domain.
Deletion of the heme domain results in a loss of sensitivity of the enzyme to titanium
citrate [84], leading to a hypothesis that CBS heme acts as a redox sensor [84, 85]. CBS
activity can also be inhibited by CO or NO binding to CBS heme [86-88]; suggesting
CBS is regulated by CO and NO. Deletion of CBS heme domain reduces activity by
~40%; however the enzyme retains the PLP binding ability [89]. The regulatory domain
contains a binding site for the allosteric cofactor S-adenosylmethionine (AdoMet) [90].
CSE is also a PLP-dependent homotetramer; each subunit is 44.5 kDa [91].
Initially CBS has been described to be localized in the brain and the nervous
system, while CSE localized to the circulatory system and peripheral tissue [92]. CBS is
highly expressed in the brain [3], while CSE is highly expressed in the liver and kidneys
[93]. However a clear tissue division may not exist [92], and most tissues have an intact
reverse transsulfuration pathway, meaning both CBS and CSE are present [94]. The
relative quantities of CBS and CSE do vary and tissues may have a dominant H2Sproducing enzyme; for example CSE protein levels are ~60 fold higher than CBS in
mouse liver, and ~20 fold higher in mouse kidney [75]. It has been suggested CSE is
absent in the brain since it is undetectable by western blotting [95], however the
conversion of [35S]-methionine to [35S]-cysteine was observed in cultured human
neurons, murine neurons, murine astrocytes and mouse brain slices [93, 94], suggesting
7

an intact transsulfuration pathway. CSE activity was also 100 fold higher in human brain
than in mouse brain [96]; animal models may not always be an accurate representation of
human physiology.
Mutations in CBS can cause severe hereditary hyperhomocysteinemia [97].
Elevated homocysteine levels in circulation are associated with major diseases including
cardiovascular disease [98], and Alzheimer’s disease [48]. Homozygous CBS knockout
in mice is lethal; CBS knockout mice suffered from growth retardation, and died within 5
weeks of birth [99]. This is most likely due to inability to metabolize homocysteine rather
than H2S-related changes since homozygous CBS knockout mice had ~40 fold the normal
plasma homocysteine levels [99]. CSE knockout mice display hypertension [26],
although an independent CSE knockout mice study found mice were normotensive [27].
CSE knockout mice also required dietary cysteine to protect against lethal myopathy, and
had a higher susceptibility to oxidative injury [27]. Mutations in CSE are very rare, but
may cause genetic cystathioninuria, which is characterized by an abnormal level of
plasma cystathionine [91, 100, 101].
CBS and CSE activity in cell culture experiments may be modulated by enzyme
inhibitors. The most commonly used inhibitors are DL-propargylglycine (PAG), βcyanoalanine (BCA), and aminooxyacetic acid (AOAA), which target the PLP binding
site of CBS and CSE. PAG and BCA have been described in the literature as specific
inhibitors of CSE, while AOAA has been described as a specific inhibitor of CBS.
Although commonly described as specific inhibitors of CBS and CSE, PAG, BCA, and
AOAA display many non-specific effects, as reviewed in detail by Whiteman et al. [92].
Since they target the PLP binding site, CBS and CSE inhibitors inhibit other PLPdependent enzymes. PAG, BCA, and AOAA are used in high millimolar concentrations
and have been used in other research fields as “specific” inhibitors of other physiological
processes [92]. It has also been shown that AOAA is a more powerful inhibitor of CSE
rather than CBS [102]. The lack of specific inhibitors of CBS and CSE make it difficult
to study their functions.
Another pathway of H2S production is through cysteine aminotransferase (CAT)
and 3-mercaptopyruvate sulfurtransferase (3-MST) [1]. 3-MST is also known as tRNA
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thiouridine modification protein (TUM1) and two splice variants have been discovered
with molecular masses of 35.4 kDa and 33.3 kDa [103]. CAT/3-MST is less widelystudied than CBS and CSE. CAT catabolizes cysteine by reaction with α-ketoglutarate to
form 3-mercaptopyruvate (3-MP) and glutamate (Figure 1.1.2-4) [104]. 3-MST transfers
the thiol from 3-mercaptopyruvate to an acceptor, which can be another thiol, forming a
persulfide, or to cyanide, to form the less toxic thiocyanate [105] (Figure 1.1.2-4). This
means reducing agents are required to liberate the sulfide from persulfides [1], and 3MST has been hypothesized to generate H2S for storage [106]. The crystal structure of 3MST revealed a complex with a Cys 248 persulfide and pyruvate, suggesting 3-MST is
the initial thiol acceptor from 3-MP, although the exact reaction mechanism has not yet
been elucidated [107]. The maximum enzymatic activity of 3-MST occurs in alkaline
conditions [1, 107]. The KM values for 3-MST using 3-MP as a substrate have been
reported as 1.2 mM using 2-mercaptoethanol as a sulfur acceptor [108], and 4.5 mM
without a sulfur acceptor [109]. Yadav et al. reported KM values for 3-MST using 3-MP
as a substrate using various sulfur acceptors; KM values ranged from 20 µM to 350 µM
depending on the acceptor [107]. CAT/3-MST pathway has been discovered to produce
H2S in the brain [106], and the vascular endothelium [110]. 3-MST has been shown to be
localized in the mitochondria and the cytoplasm [103, 111]. In 1992, cysteine
concentration in rat liver mitochondria has been determined to be ~0.7-1.0 mM [112].
Based on enzyme KM values and cellular substrate concentrations the CAT/3-MST
pathway in the mitochondria might be the only H2S-producing system where H2S
production might be favoured over other reactions [94]. A more recent study found the
mitochondrial cysteine concentration in mouse SMCs to be 177.5 ± 5.8 µM [113].
Although high concentrations of H2S can inhibit mitochondrial electron transport by
complex IV inhibition, low concentrations have been shown to stimulate mitochondrial
electron transport by donating electrons to complex II through sulfide quinone reductase
(SQR) [114]. Since 3-MST is present in the mitochondria and 3-MP has been shown to
stimulate this process, 3-MST has been hypothesized to be a regulator of mitochondrial
bioenergetics. It has been shown 3-MST stimulates angiogenesis and would healing in
mice by intraperitoneal injection of 3-MP [115]. It has been hypothesized that endothelial
dysfunction due to hyperglycemia occurs partly due to 3-MST pathway impairment. The
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combination of 3-MP and lipoic acid was able to restore normal angiogenesis and
mitochondrial function in hyperglycemia. Inhibitors of CAT (aspartate) and CSE (PAG)
has been found to reduce postischemic cerebral vasodilation, suggesting CAT/3-MST and
CSE play a role in blood-brain barrier disruption following a stroke [116]. Recently it
was found 3-MST generates H2S3 and H2S2 polysulfide in addition to H2S in mouse brain
tissues [109]. Red blood cells contain 3-MST and can produce H2S if provided with 3MP and DTT [117]. Red blood cells can also oxidize H2S by hemoglobin to polysulfides
and thiosulfate.
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Figure 1.1.2-1 Reverse transsulfuration pathway. Reaction I is the first step of the reverse
transsulfuration pathway, catalyzed by cystathionine β-synthase (CBS). Reaction II is the
second step of the reverse transsulfuration pathway, catalyzed by cystathionine γ-lyase
(CSE).
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Figure 1.1.2-2 Reactions catalyzed by cystathionine β-synthase (CBS) which produce
H2S or cysteine persulfide (thiocysteine).
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Figure 1.1.2-3 Reactions catalyzed by cystathionine γ-lyase (CSE) which produce H2S or
cysteine persulfide (thiocysteine).
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Figure 1.1.2-4 Reactions catalyzed by the CAT/3-MST pathway. Reaction I is catalyzed
by cysteine aminotransferase (CAT). Reaction II is catalyzed by 3-mercaptopyruvate
sulfurtransferase (3-MST). R represents a sulfur acceptor, which can be cyanide (CN-),
organic sulfur (eg. glutathione), or an inorganic sulfur (HSO3-).
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1.1.3 Chemical Properties of H2S
When studying H2S in biological systems it’s important to understand the physical
properties of H2S in order to design accurate experiments and draw appropriate
conclusions. H2S is a colorless, flammable, toxic gas with a characteristic smell of rotten
eggs. H2S gas is lipophilic and has a high solubility in organic solvents, allowing it to
cross cellular membranes, although it is not as highly lipophilic as NO and CO [8, 118].
H2S gas is denser than air with a vapor density of 1.19 and in solution it is a weak acid
that dissociates according to the equilibrium:

pKa1 is around 6.98 at 25 °C, 6.76 at 37 °C, while pKa2 is >17 [119, 120]. As a result H2S
is approximately 20% H2S and 80% HS- (hydrosulfide) in solution at physiological
conditions (37 °C and pH 7.4), and S2- (sulfide) is negligible. Unless otherwise specified
most researchers refer to all the species in that equilibrium collectively as “hydrogen
sulfide”. One consequence of H2S equilibrium in solution is H2S solutions release
gaseous H2S, driving equilibrium to the left, until all the hydrogen sulfide is lost from the
solution. This has been recognized as a pitfall in H2S research. It has been speculated that
it contributes to the discrepancy between experimental concentrations required to produce
biological responses and actual in vivo concentrations. This loss has been shown to be
significant in open cell culture plates, bubbling tissue baths, and Langendorff apparatus
[121]. The half-life of H2S in open cell culture plates is only 5 minutes.
Most commonly used forms of H2S in solution are sodium hydrosulfide hydrate
(NaSH•xH2O) and sodium sulfide (Na2S•9H2O). Sodium hydrosulfide is only ~60% pure
and is contaminated with elemental sulfur, yet it is the most commonly used H2S donor.
Sodium hydrosulfide crystals have a yellow appearance from elemental sulfur. It has
been hypothesized by Toohey that the biological activity attributed to hydrogen sulfide
comes from contaminating sulfane sulfur (elemental sulfur), and from oxidation of
hydrosulfide to sulfane sulfur and polysulfides [122]. The kinetics of H2S release from
sodium salts may also not be physiologically relevant. Sodium salts are thought to release
hydrogen sulfide in a large bolus [123]. Additionally sulfide salts create large local
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concentrations of Na+ [92], the effect of which in relation to H2S research has not been
studied. An alternative is synthetic H2S donors, such as GYY4137 [124, 125], which are
thought to release H2S in a slower and more physiologically relevant manner. Many other
H2S releasing molecules were developed recently due to increasing interest in H2S
research [126]. Some H2S releasing compounds are also naturally occurring, and it has
even been hypothesized that the biological activity from garlic (Allium sativum) occurs
due to H2S [127, 128]. Interest in H2S releasing compounds also stems from development
of H2S-based therapeutics [126].
H2S solutions can oxidize to polysulfides, elemental sulfur, and sulfur oxides in
the presence of oxygen. The chemical species and mechanisms involved are surprisingly
complex. Oxidation of sulfide has been studied by Chen et al. in 1972 [129]. Sulfide is
first oxidized by oxygen to elemental sulfur [129, 130]. The oxidation is catalyzed by
trace metals, as it can be inhibited by the metal chelator DTPA [130]. Sulfur can then
react with sulfide to produce polysulfides. Polysulfides exist in solution as an
equilibrium, with different chain lengths present at the same time (Equation 1.1.3-2)
[122].

Although Chen et al. initially reported formation of polysulfides with up to 5 sulfurs
[129], improved detection methods allowed the detection and characterization of
polysulfides with up to 8 sulfurs [131, 132]. Polysulfide formation is pH dependent, and
the distribution of polysulfide species is also pH dependent. In 2009 Stasko et al.
determined the initial oxidation of H2S by oxygen occurs through sulfhydryl radical
(HS•/S•-) intermediates [133]. Under this reaction mechanism H2S could be directly
oxidized to polysulfides without forming elemental sulfur intermediates.
H2S oxidation products also include sulfite (SO32-), thiosulfate (S2O32-), and
sulfate (SO42-) [129, 130]. The oxidation of H2S combined with the volatility means that
H2S solutions prepared from sulfide salts need to be made fresh before an experiment.
Increasing evidence indicates that the H2S-derived biological activity occurs at least
partly due to polysulfides generated from H2S. Some researchers have used inert gases
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and metal ion chelators to prevent oxidation of H2S, although such conditions may not be
physiologically relevant.
Given that H2S has been shown to act as an anti-oxidant, and sulfur atom in H2S
is in its most reduced -2 state, H2S can react with a number of physiologically relevant
redox signaling molecules. H2S can react with superoxide (O2-), peroxide (H2O2),
hypochlorous acid (HOCl), peroxynitrite (ONOO-), nitric oxide (NO), lipid peroxide
(LOOH), various forms of biological iron, and protein disulfides. The subject has been
reviewed in detail by Li and Landcaster [134]. The mechanisms, kinetics, and biological
relevance of many of these reactions are still unclear. Of particular interest to researchers
are reactions between H2S and NO as researchers look for evidence of H2S-NO
interaction, so called “cross-talk”. Filipovic et al. reported H2S can react with Snitrosothiols to form thionitrous acid (HSNO) [135]. HSNO is unstable and can
decompose into NO+, NO, NO-, and cause protein transnitrosation. It has been
hypothesized H2S is able to cause transnitrosation of proteins through HSNO in vivo.
Filipovic et al. also reported that H2S can react with the NO donor sodium nitroprusside
(SNP) to form nitroxyl (HNO) [136]. It has also been reported that, when catalyzed by
heme iron, H2S can react with nitrite (NO2-) to produce NO, as well as HSNO and HNO
[137]. Cortese-Krott et al. reported that the product of NO and H2S is nitrosopersulfide
(SSNO−) [138]. Although various S-N hybrid species formed from NO and H2S have
been reported in vitro at large concentrations of reactants, the physiological relevance of
such reactions has not yet been demonstrated.
Although it has previously been proposed that blood concentrations of H2S are in
the 10-100 µM range [139], it is now clear that H2S is not a circulating gasotransmitter
[120]. Introduction of H2S in tissues results in rapid H2S catabolism. This is particularly
highlighted in a study by Whitfield et al. where an extracorporeal pump was used to draw
blood from the dorsal aorta of rainbow trout, and returned across a polarographic H2S
sensor into the caudal vein [140]. H2S level was ~0.1 µM at resting state, and when H2S
was injected into caudal vein cannula, the blood H2S concentration rose to ~1.4 µM
momentarily and rapidly returned to baseline. The amount of H2S injected was
theoretically enough to raise the blood H2S concentration to ~30 µM. Half-lives of H2S
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were also much lower in whole-blood than in buffer. This study demonstrates the highly
reactive nature of H2S in biological systems. The rapid clearance of H2S from blood is
likely due to H2S oxidation by hemoglobin [117].
1.1.4 Mechanisms of H2S Signaling: S-Sulfuration
Although H2S can react with other redox signaling molecules and iron, the primary
mechanism of H2S biological activity is widely-accepted to be protein post-translational
modification [141]. Similar to S-nitrosation by NO, H2S affects cysteine thiols, where
H2S can add sulfur to cysteine thiols forming a persulfide thiol (-SSH). Initially this
process has been termed sulfhydration, which was later criticized for having incorrect
IUPAC nomenclature, and is now commonly referred to as S-sulfuration or
persulfuration. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was the first
protein shown to be S-sulfurated by Mustafa et al. in 2009 [141]. Treatment of purified
GAPDH with NaSH caused a ~7 fold increase in enzymatic activity with an EC50 of only
15 µM. S-sulfuration of GAPDH was detected using a modified biotin shift assay, and
mass spectrometry. Mass spectrometry found the active site Cys 152 (referred to as Cys
150 in the original publication) to be S-sulfurated. The modified biotin shift assay was
also used to measure basal S-sulfuration of liver proteins, and it was found that 10% to
25% of all liver proteins were S-sulfurated. The modified biotin shift assay was
introduced in the same publication, and it was proposed that the thiol blocking reagent
methyl methanethiosulfonate (MMTS) does not react with S-sulfurated (-SSH) thiols, and
only reduced thiols (-SH). After MMTS treatment the protein was treated with biotinHPDP to label S-sulfurated thiols. The nature of the selectivity of MMTS or the product
of reaction between biotin-HPDP and persulfide was not explored in the 2009
publication.
Mass spectrometry is generally used to detect S-sulfuration in vitro after treating a
purified enzyme with H2S, while variations of the biotin shift protocol have been used
combined with western blotting to detect S-sulfuration in cells. This can be problematic if
the reagents used for biotin shift labelling are not specific for S-sulfuration. The MMTS
selectivity of the modified biotin shift assay was tested by Pan and Carroll in 2013 [142].
MMTS, as well as other commonly thiol-reactive reagents, were reacted with persulfides
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(S-sulfurated thiols) and analyzed by LC-MS. It was found that MMTS is not selective to
persulfides, and persulfide thiols act as a nucleophile to produce a mixed disulfide
product (-SSCH3). The same reaction occurs between persulfides and other commonly
used thiol reactive reagents like iodoacetamide and N-ethylmaleimide. Persulfides may
also react with disulfides like DTNB to form a trisulfide linkage. Two possible
mechanisms were proposed for the observed signal in the modified biotin shift assay;
incomplete labelling of thiols with MMTS will produce a positive signal after labelling
with biotin-HPDP; or trace amount of thiols can reduce the dithiomethane linkage from
MMTS labelling, and biotin-HPDP can label the resulting free thiol. It is possible that
numerous publications on the sulfuration of proteins are actually reporting cysteine
reduction and not S-sulfuration of cysteines. The increase in modified biotin shift assay
signal with increasing H2S concentration is likely due the second mechanism. Challenges
in detecting S-sulfuration using mass spectrometry include the mass increase resulting
from S-sulfuration (31.9721 Da) is very close to that to sulfonic acid (-SO2H) (31.9898
Da). It has also been suggested that unmodified protein persulfides may not be stable
under mass spectrometry conditions [143].
In the majority of S-sulfuration studies so far, proteins were shown to be Ssulfurated using the modified biotin shift assay. For example IKCa ion channels and the
Kir 6.1 subunit of ATP channels have been shown to be S-sulfurated using the modified
biotin switch assay [29, 144]. H2S has been postulated to act as an endothelium
hyperpolarizing factor and fulfill this function through S-sulfuration. Other enzymes that
have been reported to be S-sulfurated include PTP1B, a protein tyrosine phosphatase,
where S-sulfuration of its active site cysteine inactivated the enzyme [145]. S-sulfuration
was detected by mass spectrometry, and a biotinylated iodoacetic acid probe. However, it
is unclear how an iodoacetic acid based probe can be selective for S-sulfurated thiols, and
not react with free thiols. The p65 subunit of nuclear factor kappa B (NF-κB) has been
shown to the S-sulfurated using the modified biotin shift assay, a maleimide assay for Ssulfuration and S-nitrosation, and mass spectrometry to pinpoint the modification [146].
The maleimide assay involves reaction of protein thiols with two versions of fluorophoreconjugate maleimide. First free thiols and S-sulfurated thiols are reacted with red
maleimide (Alexa Fluor® 680 C2 maleimide), ascorbate is added to denitrosate S19

nitrosothiols, and S-nitrosothiols are labelled with green maleimide (Alexa Fluor® 488
C5 maleimide or IRDye 800CW). Finally DTT is added to cleave the protein-maleimide
disulfides formed from labeling persulfides with red maleimide, and loss of red
fluorescence corresponds to S-sulfuration. H2S has been hypothesized to be an in vivo
modulator of NF-κB activity. S-sulfuration of NF-κB p65 was also studied using the
modified biotin shift assay [147].
H2S has been linked to Parkinson’s disease since human brain samples from
Parkinson’s disease patients showed reduced S-sulfuration of parkin [148]. In this study
endogenous S-sulfuration in cells and tissues was detected using a maleimide assay for Ssulfuration and S-nitrosation. The modified biotin switch assay was used to detect Ssulfuration in Hek293 cells transfected with parkin. Sites of S-sulfuration were
determined using purified protein and mass spectrometry. Liu et al. studied the effect of
H2S on bone marrow mesenchymal stem cells (BMMSCs) [149]. It was determined H2S
is required for BBMSC self-renewal and differentiation. The effect was attributed to Ca2+
channel S-sulfuration. S-sulfuration of ion channels was determined using multiple
methods including Ellman’s reagent (DTNB); although not specific to S-sulfuration, live
cells were added to a solution of DTNB to measure S-sulfuration on cell surfaces. TRPV6
calcium channel was immunoprecipitated and analyzed for S-sulfuration by a maleimide
assay where only one fluorophore-conjugated maleimide was used (Alexa Fluor® 488 C5
maleimide) to test for S-sulfuration but not S-nitrosation. After treatment with maleimide,
the protein was treated with DTT to reverse protein-maleimide disulfides formed from
reaction with persulfides. The loss of fluorescence after DTT treatment has been
correlated to S-sulfuration. Mass spectrometry was used to find S-sulfurated cysteine
residues on TRPV6 channel from cells treated with NaSH. S-sulfuration of GAPDH was
also studied using this type of assay, as well as modified biotin shift, by Mir et al. in 2014
[150]. Other proteins shown to be S-sulfurated using the modified biotin shift assay
include Keap [151, 152], MEK1 [153], PLN [154], androgen receptor (AR) [155], eNOS
[156], Kv4.3 [157], PTEN [158], and pyruvate carboxylase [159].
Zhang et al. developed a tag-switch technique for detecting S-sulfuration [160].
The technique involves reacting free thiols (-SH) and persulfides (-SSH) with a thiol
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blocking reagent. After the reaction thioether linkages are formed from free thiols, and
disulfides are formed from persulfides. After addition of a nucleophile, the nucleophile
will react with disulfides, and not thioethers, selectively labeling the persulfides. One
important consideration for the design of the assay is the first blocking reagent must give
a chemical linkage with properties different from native protein disulfides. Commonlyused thiol blocking reagents like iodoacetamide and maleimides produce linkages which
are chemically similar to native protein disulfides. This would result in native protein
disulfides being labelled with the second reagent. To generate a linkage different from
native protein disulfides, the authors used methylsulfonyl benzothiazole (MSBT) to label
free thiols and persulfides. Derivatizing with MSBT generates an activated disulfide
linkage which has high reactivity to nucleophiles. The nucleophile chosen was methyl
cyanoacetate (MCA), which was biotin-linked. Using the technique the investigators
detected S-sulfuration of GAPDH after NaSH treatment. GAPDH was S-sulfurated at
basal conditions as well, although the signal was very weak. The technique was also used
to visualize S-sulfuration in cells by fluorescent microscopy when exposed to fluoresceinlabeled streptavidin.
H2S cannot react with free cysteine thiols directly and needs additional oxidants to
S-sulfurate proteins (Equations 1.1.4-1 & 1.1.4-2). Thiols in H2S and free cysteines (-SH)
are both in their most reduced oxidation states (-2) [161]. It may be possible for H2S, in
the form of sulfide (HS-), to react with disulfides resulting in an S-sulfurated thiol and a
free thiol (Equation 1.1.4-3).

Francoleon et al. investigated the reaction of disulfides with H2S by reacting oxidized
glutathione (GSSG) and oxidized papain with H2S [162]. Papain is a cysteine protease
and a reduced cysteine is required for catalytic activity. It was found H2S can reduce
GSSG to form a glutathione persulfide (GSSH) and reduced glutathione (GSH). When
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treated with low concentrations of H2S, the enzymatic activity of papain decreased, while
S-sulfuration increased. At higher concentrations of H2S the S-sulfuration of papain
decreased, while the activity increased. It was theorized that at low H2S concentrations;
H2S acts as an S-sulfurating agent, while at higher H2S concentrations; excess H2S can
act as a reducing agent for protein persulfides and regenerate the free thiol. It has been
reported that the H2S can activate vascular endothelial growth factor receptor 2
(VEGFR2) by cleaving a disulfide bond between Cys 1045 and Cys 1024 [163]. Greiner
et al. reported that H2S can cause protein oxidation through polysulfides [143]. This is an
interesting finding since the work by Francoleon et al. suggests H2S acts as a reducing
agent. It was found different H2S donors can reduce the enzymatic activity of PTEN by
thiol oxidation through polysulfides. H2S donor GYY4137 was also able to produce
polysulfides, and the effect is not only attributed to sulfide salts. The mechanism of
oxidation was determined to be S-sulfuration of active site Cys 124, followed by
formation of an internal disulfide between Cys 124 and nearby Cys 71.
Other mechanisms of S-sulfuration have been postulated to be reaction of H2S
with protein sulfenic acids (-SOH), S-nitrosothiols (-SNO), trans-sulfuration between
proteins, and reaction of reduced protein thiols with polysulfides generated from H2S
[94]. Although H2S cannot react with reduced cysteines directly, polysulfides generated
from H2S oxidation may. Equation 1.1.4-4 shows the proposed reaction of a reduced
protein thiol with a polysulfide resulting in S-sulfuration.

In addition to S-sulfurating protein thiols H2S has been shown to react with and sulfurate
8-nitro cGMP (8-nitroguanosine 3′,5′-cyclic monophosphate) to form a novel secondary
messenger 8-SH cGMP [164]. The reaction of H2S and 8-nitro cGMP was later shown to
be mediated by polysulfides [165]. Increasing evidence shows that polysulfides are
important H2S derived molecules, and protein S-sulfuration may occur through
polysulfides. Although protein polysulfides (e.g. -SSSH) have been predicted, they have
not been reported in the literature, and S-sulfuration appears to involve the addition of
only one sulfur to cysteines (-SSH).
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1.1.5 Tissue Levels of H2S
A very wide range of H2S concentrations have been reported in blood and tissues ranging
from undetectable to as high as 600 µM [166]. This issue has been reviewed several times
and stems from the use of unreliable detection methods for H2S in biological systems
(vide infra) [92, 120, 130, 166]. Sometimes working experimental concentrations, i.e. the
concentration of exogenous H2S required to produce a biological effect, or H2S
production stimulated by the addition of cysteine, may be reported as a tissue
concentration. Most commonly reported blood H2S concentrations are in the 10-100 µM
range [166]. The human nose is very sensitive to H2S; Furne et al. reported a 1 µM
solution in pH 7.4 buffer produces a “detectable, but weak” odour, while a 5 µM solution
is “unpleasant” [167]. This observation and other experiments indicate many reported
H2S tissue concentrations are not accurate. Furthermore, calculations by researchers
suggest that the human body does not contain enough cysteine and sulfur to maintain H2S
production at the commonly reported micromolar levels [166, 167]. Micromolar H2S
concentrations are also high enough to be toxic; in cell homogenates NaSH inhibited
cytochrome c oxidase with an IC50 of only 0.32 µM [168].
When measured using detection methods that are considered more reliable,
endogenous H2S concentrations are in the submicromolar range. Furne et al. reported
brain and liver H2S concentrations following 30 s homogenation as 14 ± 3 nM and 17 ± 3
nM using gas chromatography [167]. Whitfield et al. was unable to detect H2S in trout
blood using real time measurement with a polarographic H2S sensor [140]. Wintner et al.
found rat blood H2S levels were in the 0.4–0.9 µM range using an HPLC method [169].
Experiments by Whitfield et al. also showed H2S is rapidly catabolized in the blood (vide
supra) [140]. Experiments where H2S was intravenously administered to rats while
exhaled H2S was simultaneously measured showed H2S was rapidly cleared when
intravenous administration was stopped [170]. It is now clear H2S is not a circulating
gasotransmitter and reacts rapidly in the presence of tissues [120]. Due to the reactivity of
H2S with a large number of different compounds, a clear and convenient biomarker of
H2S catabolism or turn-over does not exist [92]. While H2S tissue concentrations are low
and production by CBS and CSE is relatively low, usually relatively high H2S
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concentrations required to produce biological effects. For instance high micromolar
concentrations are required to produce vasorelaxant effects of H2S [92]. Production by
CBS and CSE may be insufficient to explain the biological activities attributed to
endogenous H2S [171].
In addition to free H2S, two other sulfide sources are present in biological
systems, acid-labile sulfide, and sulfane sulfur, also known as reductant labile sulfur or
bound sulfur [172, 173]. Acid-labile sulfide is sulfide contained in iron-sulfur clusters
contained in non-heme iron-containing proteins, which upon treatment with acid release
sulfide. Sulfane sulfur refers to a divalent sulfur atom which is bonded to another sulfur
atom. Sulfane sulfur species include persulfides (R-S-S-), polysulfides (RSnSR),
thiosulfate (S2O32-), thiosulfonates (R-S2O2-), polythionates (-SO3-Sn-SO3-), and elemental
sufur (S8). Treatment with a reducing agent such as DTT may release sulfide from
sulfane sulfur species [173]. Depending on the sample handling and analytical method,
sulfide may be released from these two sources during experiments leading to an overestimation of free H2S [120].
1.1.6 H2S Detection Methods
The most commonly used and the oldest method of H2S detection is the methylene blue
method [1, 174]. The methylene blue method is a spectrophotometric method based on
the reaction of iron (III) chloride (FeCl3) and N,N-dimethyl-p-phenylenediamine (NDPA)
in the presence of HCl. The method involves trapping of H2S from biological samples
through the use of zinc acetate, and variations of the H2S extraction and trapping
procedure has led to two versions of the method, the direct, and indirect [166]. Zinc
reacts with H2S to form zinc sulfide (ZnS). In the direct method zinc acetate is added
directly to the H2S-containing sample, proteins are removed from the sample by
precipitation with trichloroacetic acid (TCA), and the zinc sulfide is reacted with NDPA
in the presence of FeCl3 and HCl. In the indirect method a piece of filter paper is soaked
in zinc acetate and placed in a sealed flask with the sample. Due to its volatility, H2S is
slowly driven from the sample into the gas phase and reacts with the zinc acetate on filter
paper. The filter paper is then removed and reacted with NDPA in the presence of FeCl3
and HCl. The final reaction with NDPA is usually incubated for 30 minutes to allow the
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formation of methylene blue. The solution is measured spectrophotometrically at 670 nm,
and is stable for hours.
The methylene blue method has the advantages of being inexpensive, easy to use,
and requires no specialized equipment. The major flaw with the methylene blue method
is the use of acidic conditions in the direct methylene blue method may cause protein
desulfuration and release acid labile sulfur from biomolecules [120, 166, 172, 175, 176].
Effectively, the methylene blue method is measuring bound sulfur in addition to free H2S
and vastly overestimating the H2S concentration. When using the indirect methylene blue
method acids such as TCA may be added to tissues [177], which results in the same
issues as with the direct method. The detection limit for the methylene blue method is 2
µM [176], making it unsuitable for detection of submicromolar concentrations of H2S.
Methylene blue has also been reported to form dimers and trimers, and as a result may
not follow Beer’s law [178].
Another commonly used H2S detection method is the sulfur specific ion selective
electrode (ISE) [140, 179]. This method is actually selective towards S2- and requires
highly alkaline conditions to convert H2S to S2-. Similarly to the acid conditions in the
methylene blue method, the alkaline conditions employed using the ISE cause drastic
alterations in biological samples [120, 166]. The standard buffers used with the ISE are
known to cause cysteine desulfuration, for example the alkaline conditions can release
sulfide from bovine serum albumin [140]. Like the methylene blue method, the ISE is not
specific to free H2S, and use of this method for measuring free H2S leads to
overestimation. Like the methylene blue method, it is also unsuitable for real-time
measurements.
H2S can be detected by high-performance liquid chromatography (HPLC) or gas
chromatography (GC). Detection with HPLC involves derivatization with the thiolreactive

probe

monobromobimane

[169,

176,

180].

Two

equivalents

of

monobromobimane react with sulfide to form a fluorescent sulfide dibimane molecule
which can be separated and detected by HPLC with a fluorescence detector. This method
is also an endpoint method. The optimum conditions for the derivatization reaction were
found to be pH 9.5, 1% O2 atmosphere, and the presence of the metal chelator DTPA
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[176]. The limit of detection was 5 nM. The method has also been adapted to measure
acid labile sulfide and reductant labile sulfide in addition to free H2S [173]. Although the
monobromobimane level is vastly more accurate and sensitive than the methylene blue
method, Wintner et al. reported discrepancies between monobromobimane detection and
the polarographic H2S sensor when measuring Na2S spiked human blood [169]. While
the polarographic H2S sensor showed rapid tissue catabolism of H2S, monobromobimane
did not, and showed a gradual decrease in H2S level over time. The authors suggest
monobromobimane may be reacting with the sulfide-containing products of H2S
catabolism in tissues. H2S can also be detected by headspace analysis using GC when
coupled to a sulfur chemiluminescence detector [167, 175, 181, 182]. Since gaseous
headspace is being analyzed this method is specific to free H2S gas. Like HPLC, GC is an
end-point measurement.
The polarographic (amperometric) H2S sensor is a modification of the Clark-type
oxygen microsensor [140, 183, 184]. This sensor is the only commonly used real-time
method of H2S measurement. The specificity to free H2S is due to the use of a gaspermeable polymer membrane that separates the anode, cathode, and the electrolyte
solution from the sample being measured [184]. The electrolyte solution contains
ferricyanide ([Fe(CN)6]3-), which is reduced at the anode to ferrocyanide ([Fe(CN)6]4-)
and re-oxidized at the cathode, which generates a background current. After it diffuses
through the gas-permeable membrane, H2S reduces ferricyanide to ferrocyanide,
generating a current which is subtracted from the background current. Detection limits of
10 nM [184] and 14 nM [140] have been reported. Since the sensor consumes H2S it
might not be appropriate for measurement of low volume samples [166]. The use of a gas
permeable membrane has also been used to detect free H2S using the thiol-reactive probe
5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) by Faccenda et al. [185].
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1.2 Nitric Oxide
1.2.1 Introduction and Biological Functions of NO
Nitric oxide (NO) is an important gasotransmitter synthesized in mammalian tissues. A
number of studies by multiple research groups in the late 1970’s and 1980’s led to the
identification of NO as the endothelium derived relaxing factor (EDRF), and later the
arginine-NO pathway which synthesizes NO. In 1977 Murad et al. discovered NO could
activate guanylate cyclase and generate cyclic GMP [186]. However, at the time NO was
not known to be produced in the body, and was most well known as a toxic pollutant. In
1980 Furchgott and Zawadzki observed endothelium-dependent vasorelaxation, where
acetylcholine relaxed isolated blood vessels only when the endothelium was intact [187].
It was later discovered acetylcholine stimulated the release of an unknown compound
dubbed the endothelium derived relaxing factor (EDRF), which can be inhibited by
methylene blue and hemoglobin, suggesting EDRF was a free radical [188]. In 1986
Gryglewski et al. discovered EDRF can be inhibited by superoxide anion (O2-) and
protected by superoxide dismutase (SOD) [189]. In 1987, based on the accumulating
evidence, Furchgott, Ignarro, and Moncada each identified EDRF as nitric oxide [2, 190,
191]. In 1988 Moncada discovered NO is synthesized from L-arginine [192, 193]. Thus
the field of NO biochemistry was born. The 1998 Nobel Prize in medicine was awarded
to Furchgott, Ignarro, and Murad for their discoveries concerning NO. Moncada was
somewhat controversially excluded from the prize due to the policy of awarding the prize
to only three individuals.
While a vast number of physiological processes are affected by NO the major role
of NO is control of vascular tone [194]. NO is synthesized in vascular endothelium, after
which it diffuses to the surrounding vascular smooth muscle, and activates soluble
guanylate cyclase causing an increase in intracellular cGMP. The increase in cGMP
triggers a signal cascade, which causes a decrease in intracellular Ca2+ and results in
vasorelaxation [195]. NO is a major determinant of basal vascular tone, and
pharmacological inhibition of NOS raises systolic blood pressure [196]. NO production
in endothelial cells is controlled by a number of different stimuli [194], the major being
endothelial shear stress [197]. Control of vascular tone and blood pressure by NO is
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ubiquitous to all mammals, and some, but not all, non-mammalian vertebrates [198].
Penile erection is controlled by NO, and drugs used to treat erectile dysfunction such as
sildenafil (Viagra®) alter NO homeostasis [199-201]. NO synthesized in endothelial cells
also prevents platelet aggregation [202]; this protects blood vessels against thrombosis,
and atherosclerosis [203]. NO mediates angiogenesis and wound healing [204-206]. NO
produced by iNOS in macrophages is responsible for antimicrobial activity of
macrophages [207]. In the nervous system NO controls vascular tone, and acts as a
neuromodulator; affecting long-term potentiation, learning, and memory [208].
1.2.2 NO-Producing Enzymes
Nitric oxide is synthesized by three isoforms of nitric oxide synthases (NOS), named
either after their localization (endothelial NOS, neuronal NOS), or by their basal level of
NO production (inducible NOS). All nitric oxide synthases are homodimers, and require
flavin

adenine

dinucleotide

(FAD),

flavin

mononucleotide

(FMN),

and

tetrahydrobiopterin (BH4) as co-factors [201]. Two isoforms of NOS; neuronal NOS
(nNOS, NOS1), and endothelial NOS (eNOS, NOS3) are regulated by intracellular Ca2+
through calmodulin [201]. Inducible NOS (iNOS, NOS2) also binds calmodulin, however
the binding is not affected by intracellular Ca2+ concentration, and instead the enzyme is
constitutively active. Nitric oxide synthases convert L-arginine and O2 to L-citrulline and
NO, using nicotinamide adenine dinucleotide phosphate (NADPH) as a co-substrate. For
every mol NO formed NOS requires 2 mol O2 and 1.5 mol NADPH [209].
nNOS is constitutively expressed in the brain, although it is not exclusively
localized to the brain [210]. nNOS maintains synaptic plasticity and blood pressure in the
nervous system [201]. nNOS is also present in the peripheral nervous system, and has
been detected in epithelial cells of lung, uterus, stomach, in kidney macula densa cells,
pancreatic islet cells, and human skeletal muscle cells [209, 210]. Although eNOS is
largely responsible for vasodilation outside of the nervous system, accumulating evidence
shows nNOS also contributes [211]. eNOS is expressed mostly in endothelial cells and is
responsible for endothelium-dependent vasorelaxation and vasoprotective effects of NO
[201]. iNOS is expressed in macrophages and is responsible for the cytotoxic effects of
NO.
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1.2.3 Mechanisms of NO Signaling: cGMP and S-Nitrosation
The major mechanisms of NO action are through the secondary messenger cGMP and
protein post-translational modification (S-nitrosation). The vasodilation effects of NO are
mediated through the cGMP dependent pathway. NO activates soluble guanylate cyclase
(sGC) by binding to sGC heme iron in an ATP and GTP dependent manner [212].
Activation of sGC causes an increased production of the secondary messenger cGMP,
which activates cyclic GMP-dependent protein kinase (also known as Protein Kinase G,
PKG, cGK) [213]. The number of targets for PKG is vast [214]. In the case of vascular
smooth muscle relaxation, the activation of PKGI causes a decrease in intracellular Ca2+,
which decreases the activity of myosin light kinase (MLCK), decreases myosin light
chain phosphorylation and leads to vasorelaxation. Decrease in intracellular Ca2+ is
caused by multiple molecular targets of PKGI, and not a single factor. cGMP-dependent
NO signaling has been described as the “classic” NO signaling pathway [195].
NO may modify cysteine residues by S-nitrosation, which is the attachment of
NO-derived nitrosonium (NO+) to cysteine, to form S-nitrosocysteine (R-SNO). The
modification is also commonly called S-nitrosylation. S-nitrosation of a protein is
dependent on the chemical microenvironment; the presence of S-nitrosating species,
cellular compartmentalization, and the degree of cysteine reactivity [195]. S-nitrosation is
particularly gaining interest in pathophysiological states where hyper- or hypo- Snitrosation of proteins contribute to pathophysiology of various diseases [215, 216].
Rather than general hyper-S-nitrosation from increased nitosative and oxidative stress,
changes in S-nitrosation status of specific proteins are changed in disease states. Changes
in protein S-nitrosation has been implicated in the pathology of cardiovascular disease,
sickle cell anemia, cancer, pulmonary arterial hypertension, diabetes, malignant
hyperthermia, and neurodegenerative diseases like Parkinson’s disease and Alzheimer’s
disease [215, 216].
NO cannot react directly with cysteine thiols to form S-nitrosothiols. For Snitrosation to occur, NO first needs to be oxidized. The mechanisms of S-nitrosothiol
formation in vivo have been reviewed by Broniowska and Hogg [217]. Two possible Snitrosating agents are dinitrogen trioxide (N2O3) and nitrogen dioxide (NO2) which can
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be formed by the oxidation of NO by O2. N2O3 may react with thiols directly to form an
S-nitrosothiol (Equation 1.2.3-1).

Another pathway for S-nitrosothiol formation is NO2 reacting with thiols to form thiyl
radicals (RS•). Thiyl radicals may then react with NO directly with to form Snitrosothiols (Equations 1.2.3-2 & 1.2.3-3).

Although N2O3 and NO2 provide a pathway for S-nitrosothiol formation, some questions
remain about the kinetics of the initial oxidation of NO to NO2 and N2O3, which are slow
under physiological NO and O2 concentrations [217]. S-nitrosation of proteins may also
occur through transnitrosation reactions with small molecular weight S-nitrosothiols like
S-nitrosoglutathione (GSNO) (Equation 1.2.3-4).

Interestingly cytochrome c can promote the formation of GSNO through its heme iron
[218, 219]. The increased GSNO formation in-turn promotes protein S-nitrosation.
Another possible pathway for S-nitrosation is through dinitrosyl iron complexes (DNIC)
which can S-nitrosate proteins by transnitrosation [220-222]. DNIC are complexes with
NO, iron, and either small molecular weight thiols or protein thiols. The relative
contribution of various S-nitrosation mechanisms in vivo is still unknown.
1.2.4 Role of NO in Wound Healing
Wound healing is an incredibly complex and coordinated process which can be divided
into three overlapping phases; inflammation, tissue formation, and tissue remodeling
[223]. This process is controlled by numerous cytokines that act on many different cell
types. NO has been shown to be important factor in wound healing, and affect the activity
of these cytokines [206]. Even before the discovery of NO as a gasotransmitter it has
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been shown arginine-deficient animals showed impaired wound healing [224]. Increased
arginine metabolism and conversion to citrulline has been observed in wounds [225].
Urinary NO2-, a biomarker for NO, increases dramatically after injury, and remains
elevated during healing [226]. Both eNOS [227], and iNOS [228] knockout mice have
exhibited impaired wound healing. Although iNOS is highly upregulated during
inflammation, NO plays a role in all stages of wound healing [229]. The production and
action of many growth factors necessary for wound healing is NO-dependent. For
example the production of vascular endothelial growth factor (VEGF) is NO-dependent
[230], as well as the downstream effects of VEGF [231]. VEGF is one of many cytokines
responsible for angiogenesis during wound healing [223]. In addition to cytokines,
numerous enzymes and transcription factors involved in wound healing are affected by
NO. Numerous animal studies have been conducted on the efficacy of NO-releasing
materials on cutaneous wound healing [232-241]. The development of NO-releasing
wound dressings is however hampered by the inconvenient chemistry of commonly-used
NO-releasing groups. The most commonly used NO-releasing groups, diazeniumdiolates
(NONOates) and S-nitrosothiols, are simple to prepare, however exhibit short or very
short half-lives [242]. S-nitrosothiols are also temperature sensitive. The second
challenge is, NO-releasing materials cannot merely release NO to be beneficial, and must
have other properties which make it appropriate to use as a wound dressing [233].
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CHAPTER 2

MICROPLATE-BASED COLOURIMETRIC DETECTION OF FREE H2S
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2.1 Introduction
Driven by the need for sensitive and specific detection methods in H2S research we
sought to develop a new method for H2S detection. This method was inspired by lead
acetate test strips for H2S, and the use of zinc acetate in the methylene blue method. In
the lead acetate test, lead reacts with H2S to form a black PbS precipitate, which serves as
a quick chemical test for H2S [243]. Similarly, in the methylene blue method H2S reacts
with zinc acetate to form ZnS, which is further reacted to form methylene blue [174]. The
chemical basis for our assay is the reaction of Ag+ with H2S to form Ag2S. This reaction
has been used to synthesize Ag2S nanoparticles, which have a high absorbance in the low
wavelength visible and UV range [244]. The assay has been adapted to the 96-well plate
microplate format, and takes advantage of the volatility of H2S. The underside of a
microplate cover, the circular area directly over the wells, was coated with a solution
containing Nafion, glycerol, and AgNO3. Nafion is a tetrafluoroethylene based polymer
with regularly spaced perfluorovinyl side chains terminated with a sulfonate group. The
combination of a hydrophobic backbone and hydrophilic side chains results in a polymer
which forms a reverse micelle nanostructure [245]. The reverse micelle pores are 4-5 nm
in diameter and has been used for templated nanoparticle synthesis [246, 247]. Solutions
of sulfide spontaneously release gaseous H2S according to Equation 2.1-1 [121]. When
open to the atmosphere the equilibrium is driven to the left until virtually all the sulfide is
lost as H2S gas. The released H2S will interact with the bottom of the microplate cover
and react with Ag+ to produce Ag2S nanoparticles (Equation 2.1-2). The formation of
Ag2S can be monitored in real time using spectroscopy and is proportional to the H2S
concentration of the solution.
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2.2 Materials
2.2.1 Reagents
Costar 96-well plates (3370) were purchased from Corning Life Sciences. Nafion
LIQUIONTM

(LQ-1115)

dispersion

was

purchased

from

Ion

Power

Inc.

(www.nafionstore.com). Glycerol (G3700) was purchased from ACP Chemicals. AgNO3
was purchased from Fisher Scientific. Na2S•9H2O (02152580) was purchased from MP
Biomedicals.
2.2.2 CSE Purification
Recombinant CSE was purified according to the detailed protocol described by Faccenda
et al. [185].
2.2.3 Animals and Tissue Collection
Mouse livers were provided by Dr. Lisa Porter (University of Windsor). All experimental
techniques complied with the guidelines set forth by the University of Windsor animal
care committee. BALB-c mice were purchased from The Jackson Laboratory (Bar
Harbor, USA). The mice were housed at the University of Windsor animal care facility.
Mice were euthanized by CO2 inhalation. The liver was removed and placed on ice.

34

2.3 Methods
2.3.1 Nafion-Coated Microplate Cover Fabrication
Nafion dispersion (LQ-1115) was mixed with glycerol in a 4:1 ratio. AgNO3 was added
from a 100 mM solution in Milli-Q H2O to a final concentration of 3 mM. The solution
was mixed well by vortexing. 15 µL of the solution was carefully pipetted (in order not to
introduce bubbles) onto each well on the underside of a microplate cover. The cover was
dried at room temperature for at least 1 hour before use.
2.3.2 Microplate Measurements
For all H2S measurements using the assay system, the absorbance of the entire microplate
along with the Nafion-coated microplate cover was measured. All solutions were spacedout in the microplate wells. In a microplate row, a well adjacent to a sample was left
empty, and the next sample was loaded into the well following the empty well. An entire
row below or above solution-containing samples was also left empty. As a result a
maximum of 24 samples were measured per 96-well microplate. All measurements were
done using a Spectramax 384 plate reader at 310 nm.
2.3.3 Standard Curve and Specificity Test
Na2S standard solutions were diluted in 100 mM phosphate buffer (pH 7.0). 300 µL of
each dilution was pipetted into the 96-well plate and the plate was covered immediately
with the fabricated Nafion-coated cover. H2S was allowed to form from Na2S for 1 h. The
absorbance of the microplate and cover was then measured to generate a standard curve.
To test specificity of the assay system, cysteine (Sigma), reduced glutathione (Sigma),
and DTT (MP Biomedicals) were compared to Na2S using the same methodology.
2.3.4 LoD Determination
The limit of detection (LoD) for the assay was determined according to the EP17
guideline published by the National Committee for Clinical Laboratory Standards
(NCCLS) [248, 249]. The LoD (limit of the detection) is defined as the lowest analyte
concentration that can be reliably differentiated from the LoB (limit of blank). The LoB
35

is the highest apparent concentration that can be produced by a blank sample. 72
replicates of a blank sample (300 µL 100 mM pH 7.0 phosphate buffer), and 72 replicates
of a low concentration sample (300 uL 10 µM Na2S in 100 mM pH 7.0 phosphate buffer)
were used for the calculations.
2.3.5 CSE Assay
CSE was diluted to a final concentration of 0.29 µg/µL in pH 8.0 100 mM phosphate
buffer with 2 mM EDTA. PLP was added to the enzyme to a final concentration of 25
µM. 295 µL of cysteine dilutions in the same buffer (without PLP) were added to the 96well plate, and the plate including the cover was pre-incubated at 37°C for 15 minutes in
the plate reader. 5 µL of the enzyme mixture was added to each cysteine dilution and the
assay was run for 40 minutes at 37°C. Absorbance at 310 nm was measured every 20 s.
Data was fit into a Michaelis-Menten equation using the Solver function in Microsoft
Excel to calculate kinetic parameters. For determination of the kinetic parameters of CSE
the tail of each real time curve (1900-2400 s) was chosen to calculate the enzymatic rate.
2.3.6 Mouse Liver Homogenate H2S Production
An endpoint assay was conducted since homogenate solutions absorb UV light. To
accomplish this, two different microplates were used, and the Nafion-coated cover was
switched between them during the experiment. One microplate was used for absorbance
readings, and one for incubating the homogenate. Prior to the trial, the Nafion-coated
microplate cover was read on the first microplate to establish baseline absorbance. Mouse
liver was homogenized in PBS using a glass dounce homogenizer. Commercial protease
inhibitor cocktail (Sigma P8340) was added in a 1:100 ratio to the homogenate. 200 uL of
the homogenate was pipetted into the second microplate. L-cysteine was added to the
homogenate to a concentration of 5 mM. The Nafion-coated cover was placed
immediately on the second microplate with the homogenate and cysteine mixture. The
microplate was incubated at 37 °C for 40 min. Afterwards, the Nafion-coated cover was
transferred from the second microplate (with homogenate), to the first one (blank) to
measure the change in absorbance.
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2.4 Results

Figure 2.4-1 Schematic of the H2S assay. H2S is volatilized in the microplate well, and
reacts with the silver ions on the underside of the Nafion/Ag-coated microplate cover to
produce silver sulfide, which is quantified spectrophotometrically. Adapted from [250]
with permission.

37

Figure 2.4-2 A photograph of the Nafion/Ag-coated 96-well plate cover after exposure to
100 mM pH 7.0 phosphate buffer with various concentrations of Na2S, dithiothreitol
(DTT), reduced glutathione (GSH), and L-cysteine (Cys). Adapted from [250] with
permission.
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Figure 2.4-3 Corrected absorbance of the Nafion/Ag-coated 96-well plate cover after
exposure to 100 mM pH 7.0 phosphate buffer with various concentrations of Na2S,
dithiothreitol (DTT), reduced glutathione (GSH), and L-cysteine (Cys). Adapted from
[250] with permission.
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Figure 2.4-4 UV−vis spectrum of a blank microplate and cover (black, dashed), the
microplate with cover coated with Nafion containing Ag+ ions (blue, solid), and the same
microplate and cover after exposure to 300 µL of 100 µM Na2S solution in pH 7.0 100
mM phosphate buffer for 1 h (red, solid). The resulting UV−vis spectrum (red, solid) is
characteristic of Ag2S nanoparticles. Adapted from [250] with permission.
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Figure 2.4-5 Standard curve for the colourimetric microplate H2S assay. Na2S was used
as a H2S donor in 300 uL pH 7.0 100 mM phosphate buffer. Absorbance was measured
after 1 h. Error bars represent the standard deviation (n=3). Adapted from [250] with
permission.
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Figure 2.4-6 H2S generation by CSE, with various concentrations of L-cysteine,
measured by the colourimetric microplate assay. Adapted from [250] with permission.
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Figure 2.4-7 Single Michaelis-Menten plot of CSE activity using L-cysteine as a
substrate. Three plots were generated to calculate the KM and Vmax of the enzyme.
Adapted from [250] with permission.

Table 2.4-1 Kinetic parameters of recombinant CSE enzyme, and mouse liver
homogenate H2S production determined by the colourimetric microplate assay. The
values are averages of three trials (n=3), with standard deviations. L-cysteine was used as
a substrate for CSE. Homogenates were aerobically incubated with 5 mM L-cysteine.
Adapted from [250] with permission.
CSE KM
CSE Vmax
Mouse liver H2S
production

11.13 ± 0.57 mM
0.45 ± 0.01 nmol min-1
4.89 ± 0.19 nmol min-1 mL-1 homogenate
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2.5 Discussion
2.5.1 Assay Design and Microplate Cover Preparation
A Nafion dispersion (Ion Power LQ-1115) was used to fabricate Nafion films. LQ-1115
is a 15% wt. Nafion dispersion in alcohols and H2O. Casting of the dispersion and
evaporation of alcohols generates a Nafion film. Addition of AgNO3 to the mixture
resulted in cracking of the Nafion film after drying. Glycerol was added to the mixture to
prevent film cracking. With glycerol it was determined empirically that 3 mM was the
highest AgNO3 concentration that could be used without the resulting film cracking after
drying. After drying the resultant film is soft due to the glycerol and should not be
mechanically disturbed. After the addition of glycerol it is unknown if the reverse micelle
nanostructure of Nafion is maintained. Although the resultant Nafion film is stable for at
least a day, extended storage resulted in spontaneous colour change likely due to the
photoreactivity of silver. The measured wells were spaced out leaving an empty well
surrounding every well being measured (eg. Figure 2.4-2). This was done to minimize the
chance of interference from H2S diffusion from an adjacent well. As a result a 96-well
plate could only measure a maximum of 24 different wells using our procedure.
2.5.2 Optical Properties
After casting, the resulting Ag-containing Nafion film is transparent and does not alter
the absorbance properties of the microplate cover (Figure 2.4-4). After exposure to H2S a
brown colour develops. Due to the design of the assay only gaseous H2S will come in
contact and react with the silver to produce a colour change. As expected other
commonly used thiols in biochemistry do not produce a reaction and colour change
(Figure 2.4-3). Ag2S nanoparticles produce very strong absorbance in the 200-300 nm
range and broad absorbance tail [244]. The spectra produced after exposure to 100 µM
Na2S is consistent with Ag2S nanoparticle formation. Although absorbance at 200-300
nm would allow the highest sensitivity to Ag2S formation, the polystyrene microplate
used absorbs light in this spectral range (Figure 2.4-4). Measurement at 310 nm was
chosen as a compromise between maximizing detection, and minimizing interference
from the microplate cover, and possibly biomolecules, for example amino acids and
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nucleic acids absorb light in the sub-300 nm range. Due to measurement at 310 nm realtime measurements are also limited by the turbidity of the sample. Turbid samples cannot
be measured in real-time using our assay system since the absorbance of the solution is
measured simultaneously, however they can be measured in an end-point manner.
2.5.3 Limit of Detection and Linear Range
The limit of detection (LOD) of the assay was determined according to the EP17
guideline published by the National Committee for Clinical Laboratory Standards
(NCCLS) [248, 249]. The LOD was calculated to be 2.61 nmol (8.70 µM), and the linear
range of the assay was from 2.61 nmol (8.70 µM) to 30 nmol (100 µM) (Figure 2.4-5).
Larger concentration samples may produce lower absorbances (Figure 2.4-3) than 100
µM. When this occurred the colour of the reacted Nafion was not uniform and a dark ring
was produced (Figure 2.4-2). Although the spots at concentrations greater than 100 µM
appeared darker, a lower absorbance was measured. The LOD of 8.7 µM does not allow
measurement of H2S in biological samples without adding substrate to stimulate H2S
production.
2.5.4 CSE Enzyme Assay
To test the assay, the kinetic parameters of the enzyme CSE were determined using Lcysteine as a substrate, and compared to the literature values. CSE activity was measured
in real-time, the V0 was calculated from the slopes, and fit into the Michaelis-Menten
equation using the Solver function in Microsoft Excel. A KM of 11.13 ± 0.57 mM was
calculated and a Vmax of 0.45 ± 0.01 nmol min-1. Although the Vmax is very close to the
Vmax determined by Faccenda et al. (0.37 ± 0.02 nmol min-1) [185], the KM differs from
previously determined values. Previously obtained KM values are 3.79 ± 2.07 mM using
the PDMS-based DTNB method used by Faccenda et al. [185], and 2.75 mM, using the
methylene blue method [81]. This is somewhat different from the KM value determined
using our colourimetric assay. The discrepancy could be due to our rates being a
combination of enzymatic H2S production, and H2S volatilization. The enzymatic curves
generated do not represent normal enzymatic activity where after steady-state kinetics the
enzymatic activity decreases over time, and instead in our curves the enzyme activity
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appears to increase over time until after ~1700 s (Figure 2.4-6). The tail end of each
curve, from 1900 s to 2400 s, was used for V0 calculations, in order to differentiate
between the different substrate concentrations. The initial apparent increase in enzymatic
activity is likely due to the establishment of equilibrium between H2S production and
volatilization. Although described as “real time” [250], the assay could perhaps be more
accurately described as “near real-time”.
The kcat for CSE catalysis of cysteine was been reported as 0.4 s-1 by Sun et al.
[81], and 3.26 s-1 by Faccenda et al. [185]. Based on the enzyme concentration used in
our assay, volume of solution used in our assay, and the kcat determined by Sun et al. it
was calculated that, after 1900 s, a total of 5.8 nmol (19 µM) H2S has formed. Using the
kcat value determined by Faccenda et al. the total H2S formed after 1900 s was calculated
to be 47 nmol (1.6 x 102 µM). These values are 1-2 orders of magnitude lower than the
lowest cysteine concentration tested (4.0 mM). The steady-state assumption, that the
concentration of the enzyme-substrate complex ([ES]) does not change, is likely true
even after 1900 s (~31 min) from the start of the enzyme assay.
2.5.5 Mouse Liver Homogenate H2S Production
Mouse liver homogenate H2S production was measured using an endpoint variation of the
microplate assay. As commonly done in the literature, H2S production was stimulated by
the addition of L-cysteine under aerobic conditions. Using 5 mM cysteine, mouse liver
homogenate H2S production was determined to be 4.89 ± 0.19 nmol min−1 mL−1
homogenate. Furne et al. measured H2S production from mouse liver homogenate at
3.210 ± 0.162 nmol min−1 mL−1 using 10 mM L-cysteine and the polarographic H2S
sensor, a method specific to H2S gas [167]. Using our assay system we were able to
obtain similar values.

46

2.5.6 Possible Improvements in Assay Design
The design of the assay may be improved by allowing the Ag-containing Nafion to be in
contact with the solution, but separated by a gas-permeable membrane. The Nafion and
gas-permeable membrane could be moved to the bottom of the well plate. This might
eliminate some of the lag during real-time measurements. The use of Ag could also be
eliminated altogether, and replaced with a fluorescent probe. Fluorescence measurements
are generally more sensitive than absorbance, and a significant decrease in detection limit
would be expected if this could be accomplished.
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2.6 Conclusions
In this chapter we developed a method for measuring H2S in biological samples. By
coating the bottom of a microplate cover with Nafion polymer mixed with AgNO3 a
simple colourimetric assay for measuring H2S in 96-well plates was developed. The assay
has a limit of detection of 8.7 µM, which is similar to the methylene blue method, and is
linear up to 100 µM. As a demonstration of the assay, the kinetic parameters of CSE
enzyme were measured, as well as H2S production from mouse tissue homogenate in the
presence of cysteine. Our assay is simple, inexpensive, and specific to H2S gas. Although
some limitations of the assay exist, they offer opportunity for improvement.
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CHAPTER 3

REACTIONS OF H2S WITH PROTEIN THIOLS AND S-SULFURATION OF GAPDH
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3.1 Introduction
In this chapter we investigated the reactivity of H2S with protein thiols. H2S was
previously discovered to mediate biological activity by post-translational modification of
cysteine residues (S-sulfuration). The first protein discovered to be modified by H2S was
GAPDH [141]. In the original publication, purified GAPDH was S-sulfurated at Cys 152.
The site of S-sulfuration was detected by mass spectrometry. When analyzed in cells,
~30% of GAPDH was S-sulfurated under basal conditions, determined by the modified
biotin shift assay. Many other proteins, including actin and tubulin, have been shown to
be S-sulfurated at high proportions. Massive basal S-sulfuration of proteins like actin and
tubulin does not support H2S’s role as a gasotransmitter, since a gasotransmitter by
definition requires specific molecular targets [5]. Given that the levels of H2S in tissues
are in the nM range [167], it also raises the question of whether H2S production is high
enough to cause mass S-sulfuration of proteins. The modified biotin shift assay has
recently been shown to be non-specific to S-sulfuration [142], and it is possible the high
basal S-sulfuration of proteins is an artifact.
GAPDH is an important glycolysis enzyme with additional functions continually
being discovered [251-253]. GAPDH contains three cysteine residues, Cys 152, Cys 156,
and Cys 247. Some authors use a numbering system that maximizes the sequence
homology between organisms where N-terminal residues are ignored, and the conserved
residues are aligned [252]. Under this numbering system Cys 152 would be labeled as
Cys 149. Mustafa et al. refer to this cysteine as Cys 150 [141]. Cys 152 is the active site
catalytic cysteine residue, which attacks the substrate glyceraldehyde 3-phosphate [252].
A reduced Cys 152 is required for GAPDH activity, and oxidation of Cys 152 can abolish
catalytic activity [253]. This raises the question of whether H2S can react with the free
Cys 152 on GAPDH and S-sulfurate it. The sulfurs in a free cysteine and in H2S are in
their most reduced states (-2), and a direct reaction with no additional oxidants is
impossible [161].
The initial redox state of GAPDH was not explored in the initial publication;
however it is an important consideration for the redox modification of biomolecules. We
tested the possibility whether H2S can react with reduced cysteines (-SH), cysteine
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disulfides (-S-S-), or perhaps another oxidized form of cysteine (-SOH, -SNO). Work by
Francoleon et al. has shown evidence that at low H2S concentrations S-sulfuration can
occur, while at higher H2S concentrations, the excess H2S can reduce the S-sulfurated
protein thiols [162]. This is an interesting theory that has been considered in this work.
Polysulfides are gaining recognition in recent years as important H2S-derived
biomolecules [34]. It may be possible for polysulfides to react with reduced cysteine
thiols to S-sulfurate proteins. We have explored the S-sulfurating ability of polysulfides,
as well as NaSH.
In this chapter, when analyzed by mass spectrometry, GAPDH was derivatized
with excess iodoacetamide after treatments to yield carbamidomethylated persulfide
derivatives (R-S-S-CH2-CO-NH2). This was done in order to help differentiate Ssulfuration from sulfinic acid formation. Depending on mass accuracy of an instrument,
unmodified R-S-SH may be erroneously assigned to R-S-O2H due to very similar masses.
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3.2 Materials
3.2.1 Reagents
Sodium sulfide (161527), potassium polysulfide (12665), oxidized glutathione (G4376),
BSA (A9647), NAD+ (N7004), sodium arsenate (A6756), glyceraldehyde 3-phosphate
barium salt (G5376), iodoacetamide (I1149), sinapinic acid (D7927), N-ethylmaleimide
(E3876), α-cyano-4-hydroxycinnamic acid (476870), vasopressin (V0377) were
purchased from Sigma-Aldrich. NaCl (S2830) was purchased from ACP Chemicals.
Dithiothreitol (DTT) (100597) was purchased from MP Biomedicals. ZebaTM desalting
columns (89882) and tris base (BP152-1) were purchased from Fisher Scientific. C18 Zip
Tips® (ZTC18S096) were purchased from Millipore. Sequencing grade trypsin (V511A)
was purchased from Promega.
3.2.2 H2O Purity
Terrific broth for growing E. coli was made with distilled H2O. All other aqueous
solutions were made using Milli-Q H2O.
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3.3 Methods
3.3.1 Vasopressin Treatments and Mass Spectrometry
1 µM vasopressin was diluted to 200 nM with pH 7.4 100 mM sodium phosphate buffer.
Polysulfides in buffered solution were added to vasopressin in a 1:1 ratio. The solutions
were incubated 30 min at 37 °C, and purified with Millipore Zip Tips® according to
manufacturer protocol. Samples were diluted 1 part sample with 3 parts Milli-Q H2O. 1
µL of sample was spotted with 1 µL of 10 mg/mL matrix solution (α-cyano-4hydroxycinnamic acid in 60 % acetonitrile, 0.1 % trifluoroacetic acid) on a MALDI plate
and analyzed by an Applied Biosystems Voyager DE-Pro mass spectrometer in reflector
mode.
3.3.2 Polysulfide Concentration
Since polysulfides exist in equilibrium as a mixture of species, the concentration of
polysulfides used was estimated. Since potassium polysulfide (12665) is ≥42% K2S,
polysulfide concentrations were calculated based on the assumption of 100% K2S. This
over-estimates polysulfide concentrations as the presence of larger molecular weight
polysulfides will reduce the molarity of the solution.
3.3.3 GAPDH Assay Buffer Handling
GAPDH assay buffer (20 mM Tris pH 7.8, 100 mM NaCl, 1 mM NAD+, 10 mM sodium
pyrophosphate, 20 mM sodium arsenate, and 0.1 mg/mL BSA) was made fresh weekly.
Unused buffer was stored in at 4 °C in the dark. When performing the GAPDH assay, an
aliquot of the buffer were taken out to be pre-warmed at 37 °C. After completion of an
enzymatic assay any leftover pre-warmed buffer was discarded and not re-used. Milli-Q
H2O was used for buffer preparation.
3.3.4 Glyceraldehyde 3-Phosphate Preparation
Glyceraldehyde 3-phosphate (G3P) which was prepared from the barium salt according
to the manufacturer protocol (Sigma G5376). After preparation the concentration of G3P
was quantified using a standard colourimetric phosphate assay using molybdate. Aliquots
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of G3P were stored at -20 °C. After thawing of an aliquot of G3P for use in the GAPDH
enzyme assay any remaining G3P in the aliquot was not re-used and discarded.
3.3.5 GAPDH Purification
BL21(DE3) E. coli containing a pET15b vector expressing wild-type His-tagged human
GAPDH, as well as a second cell stock expressing the C156S mutant, was kindly
provided by Dr. Ann English (Concordia University). 1 L of Terrific broth containing 0.1
mg/mL ampicillin was inoculated with cells grown from an overnight pre-culture. Cells
were grown at 37 °C until OD600 reached 0.4 to 0.6, at which point expression was
induced

by

addition

of

0.4

mM

(final

concentration)

isopropyl

β-D-1-

thiogalactopyranoside (IPTG). Cells were grown for a further 4 h, pelleted by
centrifugation (3950 g, 30 min, 4 °C), supernatant was discarded and cell pellets were
frozen overnight at -84 °C. Cells were resuspended in lysis buffer (50 mM sodium
phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, 2 mM PMSF, 1 mM DTT, 100
µg/mL lysozyme, 50 µg/mL DNase I, 0.2% Triton X100), incubated on ice for 30 min,
lysed by sonication, and centrifuged (11300 g, 30 min, 4 °C). The supernatant was
purified using a nickel affinity column (Sigma P6611) strictly following the manufacturer
protocol published by Sigma-Aldrich. The protein was buffer exchanged into storage
buffer (50 mM Tris 1 mM DTT pH 7.4) using a centrifugal filter (Millipore UFC903008),
following manufacturer protocol. 2 M sorbitol (cryoprotectant) was added, and aliquots
were stored at -84 °C.
3.3.6 Reduced GAPDH Enzyme Assay
GAPDH was buffer exchanged using desalting columns (Fisher 89882) into 20 mM Tris
pH 7.8 before each trial. NaSH and PS stock solutions were diluted in 20 mM Tris pH 7.8
immediately before addition to GAPDH (0.5 µg/µL), and were added at a 1:1 volume
ratio. GAPDH was incubated with NaSH or PS for 30 min at 37 °C. For the control
untreated enzyme, buffer was used instead of NaSH or PS. 0.5 µg of the enzyme was
added to 500 µL of assay buffer (20 mM Tris pH 7.8, 100 mM NaCl, 1 mM NAD+, 10
mM sodium pyrophosphate, 20 mM sodium arsenate, and 0.1 mg/mL BSA). Buffer was
pre-warmed at 37 °C before measurements. Reaction was initiated by the addition of
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glyceraldehyde 3-phosphate (G3P), which was previously prepared from the barium salt
according to manufacturer protocol (Sigma G5376). The conversion of NAD+ to NADH
was quantified by measuring absorbance at 340 nm with an Agilent 8453 UV/vis
spectrophotometer equipped with a temperature controller set at 37 °C. Measurements
were started immediately after the addition of G3P, and each sample was measured for
120 s. The treated GAPDH enzyme samples were stored on ice while waiting to be
measured. A single set of different concentration samples was measured first, following a
replicate set of the same samples, and a second replicate of the same samples, ie. the
same concentration sample was not measured three times back-to-back.
3.3.7 Oxidized GAPDH Enzyme Assay
In the GSSG-oxidized GAPDH assay, GAPDH, in 20 mM Tris pH 7.8 was treated with
equal-volume GSSG (10 mM in 20 mM Tris pH 7.8) for 1 h at room temp. The GAPDH
assay was continued with buffer exchange, NaSH, PS, or DTT treatments, same as
reduced GAPDH assay above. In the H2O2-oxidized GAPDH assay, GAPDH, in 20 mM
Tris pH 7.8 was treated with equal-volume H2O2 (200 µM) for 30 min at room temp. The
GAPDH assay was continued with NaSH, PS, or DTT treatments, same as reduced
GAPDH assay above. In the GSNO-oxidized GAPDH assay, GAPDH, in 20 mM Tris pH
7.8 was treated with equal volume GSNO (1 mM in 20 mM Tris pH 7.8) for 30 min at 37
°C in the dark. The GAPDH assay was continued with buffer exchange, NaSH or PS
treatments, same as reduced GAPDH assay above, except NaSH and PS treatments were
done in the dark.
3.3.8 GAPDH Preparation and Digestion for Mass Spectrometry
Reduced wild-type GAPDH, or reduced C156S mutant GAPDH, or GSSG-treated
GAPDH was prepared and treated with NaSH or PS using the same conditions as per
enzyme assay. For the control untreated enzyme, buffer was used instead of NaSH or PS.
GAPDH was then treated with equal volume 40 mM iodoacetamide in 20 mM Tris pH
7.8 for 2 h at room temperature in the dark. Enzyme was buffer exchanged using
desalting columns into 50 mM ammonium bicarbonate (pH 8.0). Trypsin was added in a
10:1 protein to protease ratio, and GAPDH was digested overnight at 37 °C. GAPDH
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tryptic digest was desalted using Millipore Zip Tips® according to manufacturer
protocol.
To analyze GSNO-treated GAPDH a differential labeling protocol was used [24].
First GAPDH was treated with GSNO, then NaSH or PS, as per the oxidized enzyme
assay. For the untreated control enzyme, buffer was used instead of NaSH or PS. After
NaSH or PS treatment, GAPDH was treated with 20 mM iodoacetamide (from 200 mM
stock in 20 mM Tris pH 7.8) for 2 h at room temperature in the dark. GAPDH was buffer
exchanged into 100 mM sodium phosphate pH 7.0 using desalting columns. 10 mM
sinapinic acid (from 200 mM stock in DMSO), and 20 mM N-ethylmaleimide (from 320
mM stock in Milli-Q H2O) was added to GAPDH and the enzyme was incubated for 3 h
at room temperature in the dark. GAPDH was buffer exchanged using desalting columns
into 50 mM ammonium bicarbonate (pH 8.0) and trypsin digested overnight at 37 °C
using a 10:1 protein to protease ratio. GAPDH tryptic digest was desalted using Millipore
Zip Tips® according to manufacturer protocol.
3.3.9 Mass Spectrometry
Samples were analyzed using a Waters SYNAPT G2-Si mass spectrometer configured
for nano-Electrospray ionization operated in positive mode coupled to a Waters
nanoACQUITY UPLC system. The UPLC was configured for 1D single pump trapping
with a Waters ACQUITY UPLC Symmetry C18 2G V/M trap column coupled with a
Waters ACQUITY Peptide BEH C18. Mobile phase buffer A was 0.1% formic acid.
Mobile phase buffer B was acetonitrile 0.1% formic acid. Samples were loaded on the
trap column for 3 min at a flow rate of 5 µL/min in 97% buffer A. 60 min gradient was
run at a flow rate of 0.5 µL/min where buffer A concentration was 97% at 0 min to 65%
at 30 min, 40% at 35 min, 15% at 36 min, 15% at 41 min, and 97% at 42 min. All
samples were first analyzed in MSe mode, followed by MS/MS sequencing. Reduced and
GSSG-oxidized samples were analyzed using DDA MS/MS mode. The DDA acquisition
method for MS/MS used an include list of theoretical m/z values for precursor ions
matching the possible modifications of cys-containing peptides based on sulfide,
iodoacetamide, and glutathione treatments. GSNO-oxidized and C156S mutant samples
were analyzed by targeted MS/MS of precursor ions from MSe acquisitions.
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3.3.10 Molecular Dynamics (MD) Simulations
All structure preparation and MD calculations were performed using the Molecular
Operating Environment 2013 (MOE) program [25]. A high-resolution (1.75 Å) X-ray
crystal structure of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) complexed
with NAD+, from Homo sapiens, was obtained from the Protein Data Bank (PDB ID:
1U8F) [26]. The structure was then protonated using the default propKa [25, 27] method
in MOE, and all water molecules were removed except those in or near the catalytic and
ligand binding sites. The resulting complex was then solvated with water to four layers
deep. Exploiting the fact that GAPDH is a homo-tetramer, Cys156 of chain B (Cys156B)
was mutated to include a persulfide (-SSH) moiety, while Cys156 of chain A was
maintained in its wild-type thiol (-SH) state. The entire solvated complex was then
optimized (energy minimized) using the molecular mechanics AMBER12EHT force field
until the root mean square gradient of the total energy fell below 0.21 kJ mol-1 Å-1. The
MM optimized structure was then used as a starting structure for subsequent MD
simulations in which a standard protocol was used. More specifically, the complex
underwent an equilibration period in which temperature was gradually raised from 150 K
to 300 K over a period of 100 ps. This was then followed by a 10 ns production MD in
which the temperature was held at 300 K. A cluster analysis was then performed, and the
median of the most populated cluster was chosen as the average structure. These analyses
were performed separately on both chain A (-SH) and B (-SSH). The average structures
of these two chains were superimposed and analyzed to find the effect of the mutation on
GAPDH.
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3.4 Results
3.4.1 S-sulfuration of Vasopressin
Vasopressin was used as a model peptide for studying S-sulfuration. Vasopressin ionizes
well in MALDI-MS. Vasopressin has an amino sequence of GRPCNQFYC and forms an
internal disulfide between the cysteines. Vasopressin was reacted with varying
concentrations of polysulfides and NaSH. Figure 3.4.1-1 shows the spectra of vasopressin
after reaction with increasing amounts of polysulfides relative to vasopressin. Ssulfuration of vasopressin is first observed at ~1,000 fold polysulfides where a singly Ssulfurated vasopressin peptide (m/z 1117) is visible. Relative intensity of the S-sulfurated
peptide is ~10% of the unmodified (m/z 1084). At ~10,000 fold polysulfides the singly Ssulfurated vasopressin (m/z 1117) is now more intense at ~18% of the unmodified (m/z
1084). Doubly S-sulfurated (m/z 1150) vasopressin appears at ~10,000 fold polysulfide
concentration and the relative intensity compared to the unmodified is ~8%. Higher
concentrations of polysulfides produced more S-sulfuration; however the modification is
in low stoichiometry compared to the unmodified peptide. NaSH produced the same
results as polysulfides, requiring ~1,000 fold NaSH to observe S-sulfuration. To test the
possibility that the disulfide in vasopressin is reforming, vasopressin was reacted with
iodoacetamide to trap the cysteine persulfide. Blocking with iodoacetamide did not
increase the relative amount of S-sulfuration detected. An example spectrum is included
in Appendix A. m/z 1107 and m/z 1123 are unknown derivatives of vasopressin present
in the purchased product.
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Figure 3.4.1-1 MALDI-MS spectra of vasopressin treated with A) 10 fold (10 µM)
polysulfides B) 100 fold (100 µM) polysulfides C) 1,000 fold (1 mM) polysulfides D)
10,000 fold polysulfides (10 mM). m/z 1084 represents unmodified vasopressin, m/z
1117 represents vasopressin with a single S-sulfurated cysteine, m/z 1150 represents
vasopressin with two S-sulfurated cysteines.
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3.4.2 Reduced GAPDH Activity and Analysis by Mass Spectrometry
The activity of the reduced GAPDH enzyme was measured with and without treatment
with 50 µM NaSH. 50 µM NaSH had no effect on the kinetic parameters of GAPDH
(Figure 3.4.2-1). The control enzyme had a KM of 0.35 ± 0.03 mM and a Vmax of 51 ± 5
µM/min. After NaSH treatment the KM was 0.30 ± 0.03 mM, and the Vmax was 52 ± 6
µM/min. Reduced GAPDH enzyme activity was tested with increasing concentrations of
NaSH and polysulfides. NaSH produced a small, however statistically insignificant,
change in enzyme activity while polysulfides produced a decrease in enzymatic activity
to a minimum of ~42% of untreated enzyme at 200 µM polysulfides (Figure 3.4.2-2).
50 µM NaSH or polysulfides was used to treat the enzyme before mass
spectrometry. Peptides were labeled with iodoacetamide to trap the persulfide. It was
found that after treatment with NaSH Cys 247 was S-sulfurated, however Cys 152 and
Cys 156 were not (Table 3.4.2-1). After treatment with polysulfides Cys 247 and Cys 156
were S-sulfurated, however the active site residue Cys 152 was not (Table 3.4.2-1)
(Figure 3.4.2-3). S-sulfuration of Cys 156 correlates with a decrease in enzyme activity,
while S-sulfuration of Cys 247 appears to have no change in enzymatic activity.
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Figure 3.4.2-1 (A) Michaelis-Menten kinetics of purified GAPDH enzyme (KM = 0.35 ±
0.03 mM, Vmax = 51 ± 5 µM/min). (B) Michaelis-Menten kinetics of purified GAPDH
enzyme treated with 50 µM NaSH (KM = 0.30 ± 0.03 mM, Vmax = 52 ± 6 µM/min). The
error bars represent standard error (n=3). Adapted from [254] with permission.
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Figure 3.4.2-2 (A) Enzymatic activity of purified GAPDH (1 µg/mL) as a function of
increasing sodium hydrosulfide concentration. (B) Enzymatic activity of purified
GAPDH (1 µg/mL) as a function of increasing polysulfide concentration. The error bars
represent standard error (n=3). Adapted from [254] with permission.
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Figure 3.4.2-3 (A) MS/MS spectrum of active site peptide (m/z 918.00) from control
GAPDH enzyme. (B) MS/MS spectrum of active site peptide (m/z 933.43) from
polysulfide treated GAPDH enzyme. The mass of y ions after y7 increases by 32 Da
indicating additional sulfur on Cys 156. The mass difference between y10 and y11 does not
change indicating Cys 152 is unchanged. CAM denotes carbamidomethyl group after
iodoacetamide treatment. Adapted from [254] with permission.
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Table 3.4.2-1 Cysteine-containing tryptic peptides sequenced by ESI-MS/MS analysis of
purified GAPDH enzyme: reduced control, treated with sulfide (NaSH), treated with
polysulfides (PS). Adapted from [254] with permission.
Treatments

Sequence

IAM

VPTANVSVVDLTCR
IISNASCTTNCLAPLAK

Modification

Cysteine

Precursor
a
ion m/z
765.90
917.46

-S-CAM
247
-S-CAM
152
-S-CAM
156
NaSH
VPTANVSVVDLTCR
-S-CAM
247
765.91
IAM
-S-S-CAM
247
781.89
VPTANVSVVDLTCR
IISNASCTTNCLAPLAK
-S-CAM
152
917.48
-S-CAM
156
b
PS
VPTANVSVVDLTCR
-S-CAM
247
766.44
b
IAM
-S-S-CAM
247
782.43
VPTANVSVVDLTCR
IISNASCTTNCLAPLAK
-S-CAM
152
917.49
-S-CAM
156
933.46
IISNASCTTNCLAPLAK
-S-CAM
152
-S-S-CAM
156
a
All precursor ions reported are +2 ions unless otherwise indicated in () beside the m/z.
b 13
C isotope ion.
Abbreviations: CAM, carbamidomethyl; IAM, iodoacetamide; PS, polysulfide.
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3.4.3 GSSG-Oxidized GAPDH Activity and Mass Spectrometry Analysis
GAPDH was oxidized with GSSG to form glutathionylated GAPDH. The amount of
GSSG was chosen with intent to produce approximately 50% reduction in enzyme
activity, in order to observe a possible decrease or increase in enzymatic activity. A plot
of enzyme activity with increasing GSSG concentration is included in Appendix A.
During enzyme activity experiments 5 mM GSSG produced a larger decrease in
enzymatic activity than anticipated; the enzyme retained approximately 25% activity
compared to the untreated control (Figure 3.4.3-1). After treatment with DTT, the
GAPDH enzymatic activity increased to ~70% of untreated control at 100 µM DTT
(Figure 3.4.3-1A). Increasing the DTT concentration past 100 µM produced no further
increase in enzymatic activity. NaSH treatment produced very similar results; activity
increased to approximately ~60% of untreated control at 100 µM NaSH, and to ~70% of
untreated control at 500 µM (Figure 3.4.3-1B). After polysulfide treatment, activity
increased to approximately ~55% of untreated control at 100 µM and 65% of untreated
control at 500 µM (Figure 3.4.3-1C). After mass spectrometry analysis glutathionylated
Cys 247 was detected (m/z 889.92) (Table 3.4.3-1). NaSH treatment caused S-sulfuration
of Cys 247 (m/z 781.92), while polysulfide treatment caused S-sulfuration of Cys 247
(m/z 781.88) and Cys 156 (m/z 933.46).
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Figure 3.4.3-1 (A) Enzymatic rate of purified wild-type GAPDH (1 µg/mL), GSSGtreated, as a function of increasing DTT concentration. (B) Enzymatic rate of purified
wild-type GAPDH (1 µg/mL), GSSG-treated, as a function of increasing NaSH
concentration. (C) Enzymatic rate of purified wild-type GAPDH (1 µg/mL), GSSGtreated, as a function of increasing polysulfide (PS) concentration. The error bars
represent standard error (n=3). Rate is expressed as percentage of untreated control.
Adapted from [254] with permission.
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Table 3.4.3-1 Cysteine-containing tryptic peptides sequenced by ESI-MS/MS analysis of
purified GAPDH enzyme: GSSG-treated control, GSSG-treated and treated with sulfide
(NaSH), GSSG-treated and treated with polysulfides (PS). Adapted from [254] with
permission.
Treatments

Sequence

Modification

Cysteine

GSSG
IAM

VPTANVSVVDLTCR
VPTANVSVVDLTCR
VPTANVSVVDLTCR
VPTANVSVVDLTCR

-S-H
-S-CAM
-S-S-Glu
-S-S-Glu

247
247
247
247

IISNASCTTNCLAPLAK

-S-CAM
-S-CAM
-S-H
-S-CAM
-S-S-CAM
-S-S-Glu
-S-CAM
-S-H
-S-H
-S-CAM
-S-S-CAM
-S-S-Glu
-S-S-Glu

152
156
247
247
247
247
152
156
247
247
247
247
247

GSSG
NaSH
IAM

VPTANVSVVDLTCR
VPTANVSVVDLTCR
VPTANVSVVDLTCR
VPTANVSVVDLTCR
IISNASCTTNCLAPLAK

GSSG
PS
IAM

VPTANVSVVDLTCR
VPTANVSVVDLTCR
VPTANVSVVDLTCR
VPTANVSVVDLTCR
VPTANVSVVDLTCR
IISNASCTTNCLAPLAK

Precursor
a
ion m/z
737.39
765.91
889.92
593.61
(+3)
917.46
737.39
765.93
781.92
889.95
888.95
737.39
765.90
781.88
889.94
593.62
(+3)
888.96

-S-H
152 or 156
-S-CAM
152 or 156
IISNASCTTNCLAPLAK
-S-CAM
152
917.49
-S-CAM
156
933.46
IISNASCTTNCLAPLAK
-S-CAM
152
-S-S-CAM
156
a
All precursor ions reported are +2 ions unless otherwise indicated in () beside the m/z.
Abbreviations: CAM, carbamidomethyl; Glu, glutathione; GSSG, glutathione disulfide;
IAM, iodoacetamide; PS, polysulfide.
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3.4.4 H2O2-Oxidized GAPDH Activity
GAPDH was oxidized with H2O2 to form sulfenic acid (-SOH) derivatives of cysteine,
and perhaps higher oxidation state sulfinic acid (-SO2H), and sulfonic acid (-SO3H). H2O2
concentration was chosen to produce ~50% inactivation. After treatment with DTT an
increase from ~35% of untreated control to ~60% of untreated control was observed with
the lowest concentration tested of 5 µM (Figure 3.4.4-1A). Additional concentration of
DTT did not increase activity past ~60% of control. Treatment with 5 µM NaSH
increased GAPDH activity from ~45% to ~60% of untreated control with no further
increase observed (Figure 3.4.4-1B). Treatment with polysulfides did not significantly
alter the activity of H2O2-oxidized GAPDH (Figure 3.4.4-1C).
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Figure 3.4.4-1 (A) Enzymatic rate of purified wild-type GAPDH (1 µg/mL), H2O2treated, as a function of increasing DTT concentration. (B) Enzymatic rate of purified
wild-type GAPDH (1 µg/mL), H2O2-treated, as a function of increasing NaSH
concentration. (C) Enzymatic rate of purified wild-type GAPDH (1 µg/mL), H2O2treated, as a function of increasing polysulfide (PS) concentration. The error bars
represent standard error (n=3). Rate is expressed as percentage of untreated control.
Adapted from [254] with permission.
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3.4.5 GSNO-Oxidized GAPDH Activity and Mass Spectrometry Analysis
GAPDH was pre-treated with GSNO to test whether S-nitrosation may affect the Ssulfuration of GAPDH. Both NaSH and polysulfides produced a biphasic response where
activity initially decreased with increasing sulfide concentration, but later increased as
sulfide concentration was increased past 50 µM (Figure 3.4.5-1). NaSH treatment
decreased GAPDH activity from ~55% of untreated control to ~40% of untreated control
at 50 µM NaSH (Figure 3.4.5-1A). At 200 µM NaSH activity increased to ~80% of
untreated control. After 50 µM polysulfide treatment, GAPDH activity decreased from
~70% of untreated control to ~20% of untreated control (Figure 3.4.5-1B). Increasing
polysulfide concentration to 500 µM produced ~60% activity relative to untreated
control.
Peptides were labeled for mass spectrometry using a differential labeling protocol.
Free thiols were first reacted with iodoacetamide, sinapinic acid was used to de-nitrosate
S-nitrosothiols and N-ethylmaleimide was used to label de-nitrosated cysteine residues.
Using this protocol, S-sulfurated cysteines will be trapped with iodoacetamide, while Snitrosated cysteines will be labeled with N-ethylmaleimide. After GSNO treatment Cys
247, Cys 152, and Cys 156 were found labeled with N-ethylmaleimide, indicating Snitrosation (Table 3.4.5-1). Cys 152 reacted with carbamidomethyl was also sequenced
(m/z 951.48), indicating a free thiol, while Cys 156 was only detected labeled with Nethylmaleimide. After NaSH and polysulfide treatments the same set of peptides were
sequenced as the control (Table 3.4.5-1). No S-sulfuration was detected.
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Figure 3.4.5-1 (A) Enzymatic rate of purified wild-type GAPDH (1 µg/mL), GSNOtreated, as a function of increasing NaSH concentration. (B) Enzymatic rate of purified
wild-type GAPDH (1 µg/mL), GSNO-treated, as a function of increasing polysulfide
(PS) concentration. The error bars represent standard error (n=3). Rate is expressed as
percentage of untreated control. Adapted from [254] with permission.
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Table 3.4.5-1 Cysteine-containing tryptic peptides sequenced by ESI-MS/MS analysis of
purified GAPDH enzyme, control GSNO, GSNO-treated and treated with sulfide
(NaSH), GSNO-treated and treated with polysulfide (PS). Adapted from [254] with
permission.
Treatments

Sequence

GSNO
IAM
SA
NEM

VPTANVSVVDLTCR
IISNASCTTNCLAPLAK

Modification

Cysteine

Precursor
a
ion m/z
799.91
951.48

-S-NEM
247
-S-CAM
152
-S-NEM
156
IISNASCTTNCLAPLAK
-S-NEM
152
985.49
-S-NEM
156
GSNO
VPTANVSVVDLTCR
-S-H
247
737.39
NaSH,
VPTANVSVVDLTCR
-S-NEM
247
799.91
IAM,
IISNASCTTNCLAPLAK
-S-CAM
152
951.48
SA
-S-NEM
156
NEM
IISNASCTTNCLAPLAK
-S-NEM
152
985.49
-S-NEM
156
GSNO
VPTANVSVVDLTCR
-S-NEM
247
799.91
PS
IISNASCTTNCLAPLAK
-S-CAM
152
951.48
IAM
-S-NEM
156
SA
IISNASCTTNCLAPLAK
-S-NEM
152
985.49
NEM
-S-NEM
156
a
All precursor ions reported are +2 ions unless otherwise indicated in () beside the m/z.
Abbreviations: CAM, carbamidomethyl; GSNO, S-nitrosoglutathione; IAM, iodoacetamide;
NEM, N-ethylmaleimide; SA, sinapinic acid; PS, polysulfide.
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3.4.6 C156S Mutant GAPDH Activity and Mass Spectrometry Analysis
A C156S mutant of GAPDH was used to test whether it was possible to S-sulfurate Cys
152, and what effect the modification has on enzymatic activity. It was found the C156S
mutant of GAPDH had the same kinetic parameters, within experimental error, as the
wild-type enzyme (KM = 0.23 ± 0.08 mM, Vmax = 49 ± 8 µM/min) (Figure 3.4.6-1). After
NaSH treatment the activity of C156S GAPDH gradually decreased to 70% of untreated
enzyme at 500 µM NaSH (Figure 3.4.6-2A). Treatment with 10 µM polysulfides caused a
drop in C156S GAPDH activity to 25% of untreated control (Figure 3.4.6-2B). Increasing
polysulfide concentration past 100 µM caused an increase in enzymatic activity.
Mass spectrometry confirmed the mutation of cysteine 156 to a serine. After
NaSH or polysulfide treatments S-sulfuration of active site Cys 152 was detected (m/z
896.95) (Table 3.4.6-1). S-sulfuration of Cys 247 was also detected after NaSH, or
polysulfide treatments (m/z 781.89).
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Figure 3.4.6-1 Michaelis-Menten kinetics of purified C156S mutant of GAPDH enzyme
(KM = 0.23 ± 0.08 mM, Vmax = 49 ± 8 µM/min). The error bars represent standard error
(n=3). Adapted from [254] with permission.
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Figure 3.4.6-2 (A) Enzymatic activity of purified C156S GAPDH (1 µg/mL) as a
function of increasing NaSH concentration. (B) Enzymatic activity of purified C156S
GAPDH (1 µg/mL) as a function of increasing PS concentration. The error bars represent
standard error (n=3). Adapted from [254] with permission.

75

Table 3.4.6-1 Cysteine-containing tryptic peptides sequenced by ESI-MS/MS analysis of
purified C156S GAPDH enzyme; control, treated with sulfide (NaSH), treated with
polysulfides (PS). Adapted from [254] with permission.
Treatments

Sequence

Modification

Precursor
a
ion m/z
IAM
VPTANVSVVDLTCR
-S-H
247
737.39
VPTANVSVVDLTCR
-S-CAM
247
765.90
IISNASCTTNSLAPLAK
-S-H
152
852.45
IISNASCTTNSLAPLAK
-S-CAM
152
880.96
IAM
VPTANVSVVDLTCR
-S-H
247
737.39
NaSH
VPTANVSVVDLTCR
-S-CAM
247
765.90
-S-S-CAM
247
781.89
VPTANVSVVDLTCR
IISNASCTTNSLAPLAK
-S-H
152
852.45
IISNASCTTNSLAPLAK
-S-CAM
152
880.96
-S-S-CAM
152
896.95
IISNASCTTNSLAPLAK
IAM
VPTANVSVVDLTCR
-S-H
247
737.39
PS
VPTANVSVVDLTCR
-S-CAM
247
765.90
-S-S-CAM
247
781.89
VPTANVSVVDLTCR
IISNASCTTNSLAPLAK
-S-H
152
852.45
IISNASCTTNSLAPLAK
-S-CAM
152
880.96
-S-S-CAM
152
896.95
IISNASCTTNSLAPLAK
a
All precursor ions reported are +2 ions unless otherwise indicated in () beside the m/z.
Abbreviations: CAM, carbamidomethyl; IAM, iodoacetamide; PS, polysulfide.
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Cysteine

3.4.7 Additional MS/MS Spectra
Individual MS/MS spectra have been included in Appendix A. Identical precursor ions
sequenced in multiple samples are only shown once.
3.4.8 Molecular Dynamics Simulations of GAPDH
GAPDH S-sulfuration was studied computationally using a molecular dynamics
simulation to examine the effect of S-sulfuration of Cys 156 on the structure of GAPDH.
Two important areas of the enzyme were examined; the NAD+ binding site and the
catalytic site. Three important residues in the NAD+ binding were examined; Arg 13, Asp
35, and Asn 316 [255]. After S-sulfuration of Cys 156, the residues changed position
<0.5 Å, including the Cys 152 to Cys 156 distance (Figure 3.4.8-1). The Cys 152 to Asn
316 distance did increase by 0.7 Å. From these results the NAD+ binding site did not
change significantly after Cys 156 S-sulfuration. Critical catalytic residues Cys 152 and
His 179, as well as residues Ser 151, Cys 152, Thr 153, Thr 211 responsible for inorganic
phosphate binding (Pi site) were examined [256]. After S-sulfuration of Cys 156, the Cys
152 to His 179 distance increased by 0.5 Å (Figure 3.4.8-2). Residues in the GAPDH Pi
site Ser 151, Cys 152, and Thr 153 do not change significantly relative to each other
(<0.5 Å) after S-sulfuration of Cys 156, with the exception of the distance from Thr 153
to Thr 211, which does increase by 0.78 Å. The pKa of Cys 152 was studied
computationally using the propKa algorithm. The pKa of Cys 152 was 5.81 in the wildtype GAPDH enzyme, while the pKa of Cys 152 was 6.31 in the GAPDH enzyme Ssulfurated at Cys 156. The pKa of the catalytic cysteine was observed across all time
scales and was found to be 0.5 higher on average when Cys 156 was S-sulfurated.
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Figure 3.4.8-1 Representative structure taken from Molecular Dynamics (MD)
simulation of GAPDH showing residues from two NAD+ binding sites overlaid, gray
carbons represent the structure with free (-SH) Cys 156, while brown carbons represent
the structure with S-sulfurated (-SSH) Cys 156. Distances in Å were measured between
critical NAD+ binding residues (Arg 13, Asp 35, Asn 316) as well as Cys 152 and Cys
156. Only one protein backbone is shown. Reprinted from [254] with permission.
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Figure 3.4.8-2 Representative structure taken from Molecular Dynamics (MD)
simulation of GAPDH showing residues from two active sites overlaid, gray carbons
represent the structure with free (-SH) Cys 156, while brown carbons represent the
structure with S-sulfurated (-SSH) Cys 156. Distances in Å between critical catalytic
residues Cys 152 and His 179 were measured. Distances between residues in the Pi site
(Ser 151, Cys 152, Thr 153, Thr 211) were also measured. Only one protein backbone is
shown. Reprinted from [254] with permission.
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3.5 Discussion
3.5.1 S-Sulfuration of Vasopressin
Vasopressin was used as a model peptide for the S-sulfuration of oxidized thiols. In our
experiments vasopressin was S-sulfurated by NaSH and polysulfides, however high
concentrations of NaSH or polysulfides were required to produce vasopressin Ssulfuration (Figure 3.4.1-1). At least 1000 fold NaSH or polysulfide was required to
detect vasopressin S-sulfuration by MALDI-MS. These results show that S-sulfuration of
oxidized protein thiols is possible by NaSH and polysulfides. S-sulfuration at low
concentration of sulfide, and protein thiol reduction at high concentration, as described by
Francoleon et al. [162] was not detected with vasopressin.
3.5.2 S-Sulfuration of Reduced GAPDH
In our experiments with reduced GAPDH, it was found that NaSH had no significant
effect on reduced GAPDH activity, even with 500 µM NaSH (Figure 3.4.2-2A). 50 µM
NaSH also had no effect on the kinetic parameters of GAPDH (Figure 3.4.2-1). Since
polysulfides have been postulated to be important H2S-derived signaling molecules, we
tested the effect of polysulfides on GAPDH activity. It was found polysulfides
significantly decreased the activity of GAPDH (Figure 3.4.2-2B). When analyzed by ESIMS/MS it was found active site Cys 152 was not S-sulfurated by either NaSH or
polysulfides (Table 3.4.2-1). Cys 247 was S-sulfurated in the NaSH treated sample, while
Cys 247 and Cys 156 were S-sulfurated after polysulfide treatment. Cys 156 S-sulfuration
correlated with a decrease in enzymatic activity. These results indicate that polysulfides
are a stronger S-sulfurating agent than NaSH.
Since S-sulfuration of reduced GAPDH at Cys 247 was observed this raises the
question of how NaSH can react with cysteine thiols, since both NaSH and cysteine thiols
are in fully reduced states [161]. NaSH is only 60% pure and is contaminated with
elemental sulfur; it is highly likely polysulfides are formed in solution when NaSH is
dissolved. We therefore propose that NaSH mediated S-sulfuration of free cysteine occurs
from NaSH-derived polysulfides. This idea is consistent with our results where
polysulfides produce more S-sulfuration (both Cys 156 and Cys 247) than NaSH (only
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Cys 247). It is however possible that S-sulfuration of Cys 156 is also occurring in the
NaSH-treated sample, since the parent peptide (m/z 933) was detected in MS
measurements, but was below intensity threshold to trigger MS/MS sequencing (data not
shown). The stoichiometry of the modification may be too low to affect enzyme activity.
3.5.3 S-Sulfuration of Glutathionylated GAPDH
After oxidation of GAPDH with GSSG to form glutathionylated cysteines it was found
NaSH and polysulfides had near equal ability to restore GAPDH activity as DTT (Figure
3.4.3-1). Activity increased proportionally with the addition of NaSH or polysulfides
from ~25% of control untreated enzyme to a maximum of ~70%. This represents ~3 fold
increase in enzymatic activity from the GSSG-treated enzyme. We speculate that the fold
increase in enzymatic activity may be increased if the initial oxidation of GSSG is
stronger. It is unknown why 100% restoration of enzymatic activity with DTT was not
observed. During treatments and buffer exchanges the control samples were subject to the
same sample handling steps to minimize error.
Mass spectrometry analysis revealed glutathionylation of Cys 247 (Table 3.4.3-1)
after GSSG treatment. After NaSH or polysulfide treatment glutathionylation of Cys 247
was still detected, meaning NaSH and polysulfides did not reduce all protein-glutathione
disulfides. Similarly to the reduced GAPDH results, NaSH treatment produced Ssulfuration of Cys 247, while polysulfides S-sulfurated Cys 247 and Cys 156. When
treated with NaSH or polysulfides, oxidized protein thiols therefore have the potential to
be both reduced and S-sulfurated. A complex mixture of oxidized, reduced, and Ssulfurated thiols is present (Table 3.4.3-1). The resultant enzymatic activity is therefore
expected to be determined by the relative contribution of each modification. In addition,
free unmodified thiols (-SH) were detected. These could be from incomplete labeling
with iodoacetamide or de-glutathionylation of the enzyme after iodoacetamide treatment.
3.5.4 H2O2-Oxidized GAPDH Activity
After H2O2 treatment DTT was partially able to restore H2O2-oxidized GAPDH activity
(Figure 3.4.4-1). NaSH was able to restore GAPDH activity to a much smaller extent
than DTT. Polysulfides did not affect H2O2-oxidized GAPDH activity. Large reactivation
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was not observed, likely due a mixture of sulfenic, sulfinic, and sulfonic acid derivatives
being formed. Sulfinic and sulfonic acid derivatives are considered chemically
irreversible, while sulfenic acids may be reduced by reducing agents [257]. The results
suggest NaSH is a stronger reducing agent than polysulfides for sulfenic acids, although
additional experiments would be required to prove this. H2O2 oxidized GAPDH was not
studied using mass spectrometry.
3.5.5 Reaction of NaSH or Polysulfides with S-Nitrosated GAPDH
GSNO pre-treated GAPDH showed a biphasic response to increasing NaSH and
polysulfide concentrations (Figure 3.4.5-1). Initially, activity decreased with increasing
NaSH or polysulfide concentration until 50 µM, after which, activity increased with
concentration. This may be due to S-nitrosothiols promoting S-sulfuration at low sulfide
concentrations, and sulfide acting as a reducing agent at high concentrations. However,
when analyzed by mass spectrometry no S-sulfuration was detected (Table 3.4.5-1). For
mass spectrometry analysis 50 µM NaSH or polysulfides was used, which is the point of
lowest activity, and presumably highest S-sulfuration. One possibility is that the
carbamidomethyl disulfide was not stable under the extra sample handling steps. To the
author’s knowledge this is the first time labeling with iodoacetamide and NEM has been
used to try to simultaneously detect S-nitrosation and S-sulfuration. The method perhaps
needs to be validated with a known S-sulfurated enzyme (eg. reduced GAPDH treated
with polysulfides). The second possibility is that S-nitrosation does not promote Ssulfuration, and instead an unexpected chemical species was formed. Work by Filipovic
et al. identified the product of the reaction of H2S with GSNO as thionitrous acid
(HSNO) and reduced glutathione (GSH) [135].
3.5.6 S-Sulfuration of Cys 152 in C156S GAPDH
During all our experiments with the wild-type enzyme no S-sulfuration of Cys 152 was
observed. In order to observe the effects of Cys 152 S-sulfuration, a C156S mutant was
purified. After treatment with NaSH the C156S mutant showed a gradual decrease in
enzymatic activity (Figure 3.4.6-2). After polysulfide treatment the C156S mutant
showed a rapid decrease in enzymatic activity at low concentrations and a gradual
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increase at high concentrations. The response was more drastic to NaSH and polysulfides
than the wild-type enzyme. When analyzed by mass spectrometry Cys 152 was Ssulfurated. These results correlate Cys 152 S-sulfuration with a decrease in enzymatic
activity, contrary to previous literature results [141]. However, our results are in
agreement with work by Valentine et al. from 1987 [258], where persulfides, generated
through interaction of pyridoxal phosphate and cystine, inhibited GAPDH.
3.5.7 Role of GAPDH Cys 156
In our experiments with the wild-type GAPDH enzyme it was observed Cys 156 was Ssulfurated but Cys 152 was not. Results after GSNO treatment also indicate that Cys 156
is more readily S-nitrosated than Cys 152. After mutating Cys 156 to a serine, Cys 152
was S-sulfurated under our conditions. These experiments show Cys 156 is more reactive
than Cys 152. We therefore propose a new role for Cys 156 where Cys 156 is a protective
thiol for the adjacent catalytic Cys 152. This proposed function needs to be verified in
vivo. Cys 156 is conserved and present in E. coli., B. stearothermophilus, lobster, rabbit,
and human GAPDH [252], supporting our hypothesis. Cys 247 on the other hand is not
conserved. If Cys 156 is more reactive than Cys 152, we can expect Cys 156 to have a
lower pKa than Cys 152. This was not investigated in the present study, but is an
interesting question that could be studied in the future.
3.5.8 NaSH and Polysulfide S-Sulfuration
In experiments with reduced and oxidized GAPDH, polysulfides produced S-sulfuration
of Cys 156, while NaSH did not. In enzymatic assay experiments with reduced, GSNOoxidized, and C156S mutant of GAPDH, polysulfides produced stronger decreases in
enzymatic activity than NaSH. The results show that polysulfides are a stronger Ssulfurating agent than NaSH. Since NaSH was able to S-sulfurate reduced GAPDH at
Cys 247, NaSH may be able to S-sulfurate thiols through NaSH-derived polysulfides.
Based on these results, one can speculate that pure H2S will be an even weaker Ssulfurating agent than NaSH, since NaSH is only ~60% pure once can expect it to form
polysulfides more readily. Although it was not tested in the present study, Na2S-induced
S-sulfuration could be used to test this theory.
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3.5.9 Effect of Enzyme Buffer on Treatments
In this study all treatments of GAPDH were performed in 20 mM Tris buffer at pH 7.8.
Treatment of the GAPDH enzyme in GAPDH assay buffer (20 mM Tris pH 7.8, 100 mM
NaCl, 1 mM NAD+, 10 mM sodium pyrophosphate, 20 mM sodium arsenate, and 0.1
mg/mL BSA) may produce undesired reactions with buffer components such as arsenate.
Since GAPDH was not supplemented with the co-enzyme NAD+, we explored the
possibility that NAD+ binding may change the structure of GAPDH, and in turn change
the response to NaSH or polysulfides. In an experiment where GAPDH was in 20 mM
Tris buffer at pH 7.8 supplemented with NAD+, treatment with NaSH produced the same
results as the Tris buffer without NAD+ (Appendix A).
3.5.10 Computational Chemistry
A molecular dynamics (MD) simulations was performed to examine the effect of Cys 156
S-sulfuration on GAPDH structure. The NAD+ binding site was examined since the
limiting step of GAPDH catalysis is NADH release [252]. It was found that the structure
of the NAD+ binding site does not change significantly after Cys 156 S-sulfuration. In the
GAPDH active site, the hydrogen bond between the thiolate anion of Cys 152 and
protonated imidazole of His 179 increases by 0.5 Å upon Cys 156 S-sulfuration. This
increase in the hydrogen bonding distance would disrupt the ability of His 179 to stabilize
the Cys 152 thiolate negative charge. Consequently, the pKa of the Cys 152 thiolate will
increase, reducing its nucleophilicity. MD simulations show the pKa of Cys 152 increased
by 0.5, from 5.81 in the unmodified enzyme to 6.31 in the S-sulfurated enzyme. This may
help explain the reduced enzymatic rate upon Cys 156 S-sulfuration. In the phosphate
binding site (Pi site) Thr 211 shifts 0.78 Å away from Thr 153. This may also affect the
effectiveness of the Pi site to stabilize charges from inorganic phosphate. The MD
simulation was performed on a single crystal structure. Since GAPDH is a homotetramer
one subunit was S-sulfurated and compared to the wild-type subunit within the same
enzyme homotetramer. After the simulation was completed the two subunits were
compared. It would be interesting to perform two separate simulations, where the same
subunit is modified, and compare the results to see if they agree with the single
simulation.
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3.6 Conclusions
In this chapter we investigated the reported S-sulfuration of GAPDH using a purified
GAPDH enzyme. The effect of the initial redox state of the enzyme on S-sulfuration was
examined. It was found that NaSH treatment did not significantly alter the enzymatic
activity of reduced GAPDH. Treatment with polysulfides caused a decrease in GAPDH
enzymatic activity. Treatment with NaSH caused S-sulfuration of Cys 247, while
treatment with polysulfides caused S-sulfuration of Cys 156 and Cys 247. S-sulfuration of
active site Cys 152 was not detected in the wild-type enzyme. Both NaSH and
polysulfides were able to restore the activity of glutathionylated GAPDH with similar
effectiveness as DTT. Similarly to the reduced enzyme, treatment of the glutathionylated
enzyme with NaSH caused S-sulfuration of Cys 247, while treatment with polysulfides
caused S-sulfuration of Cys 156 and Cys 247. Using a C156S mutant of GAPDH, NaSH
and polysulfides were able to cause S-sulfuration of active site Cys 152, however a
decrease in enzymatic activity was observed, and not an increase as previously reported.
S-sulfuration of Cys 152 and Cys 156, both cause decreases in enzymatic activity. Based
on our results, polysulfides are a stronger S-sulfurating agent than NaSH. S-sulfuration of
reduced thiols by NaSH may be due to NaSH-derived polysulfides. We also propose a
new role for GAPDH Cys 156, as a protective thiol for the catalytic residue Cys 152.
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CHAPTER 4

ENRICHMENT OF SULFUR-CONTAINING PEPTIDES BY GOLD
NANOPARTICLES FOR MASS SPECTROMETRY ANALYSIS
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4.1 Introduction
Cysteines occur at a relative low frequency in proteins, however approximately 97% of
human proteins contain at least one cysteine residue [259]. The relative amount of
cysteine-containing proteins has been correlated with organism complexity. For example
cysteines account for 0.5% of protein amino acids in archaebacterial, increasing to 2.26%
in mammals. This suggests an important evolutionary role for cysteine residues, where
the chemistry of cysteine residues allows for more complex protein functions. Cysteine
residues serve a number of important roles in proteins. Cysteines are involved in
maintaining protein structure by forming disulfide bonds and functional motifs, for
example zinc fingers. Cysteine residues also function as redox switches, and are subject
to a number of post-translational modifications [215, 257, 260-265]. Important cysteine
modifications include disulfide formation, S-nitrosation, S-glutathionylation, sulfenic,
sulfinic and sulfonic acid formation. Although once considered a mostly detrimental
event in disease states and aging, macromolecule oxidation is now considered an
important regulatory mechanism in healthy tissues [266]. Identification of modified
cysteine residues and validation of their biological significance is important in
elucidating the complex redox-dependent modifications that occur in the cell.
The most accurate method for identifying post-translational modification sites is
mass spectrometry. Mass spectrometry allows unambiguous identification of protein
modification sites, without the need to generate and test mutants of a protein. Although
mass spectrometry is an extremely sensitive technique, the relative abundance of proteins
of interest may be very low in comparison to background protein. Protein of interest may
be present in detectable quantities, however may not appear in the MS spectra due to high
background. This is especially an issue in methods like MALDI-MS, where usually there
is no chromatography step to separate peptides from each other. In addition to having low
abundance, modified proteins may also be in low stoichiometry compared to unmodified.
This makes sample preparation and enrichment strategies important, in order to reduce
sample complexity by removing abundant structural and housekeeping proteins, which
aids in detection of low-abundance proteins of interest [265].

87

In recent decades there has been tremendous growth in the area of nanoparticle
research, due to advances in synthesis and characterization methods. One of the most
widely studied types of metal nanoparticles are gold nanoparticles (AuNPs). Ease of
synthesis, and useful properties such as surface plasmon resonance and inertness make
them attractive for use in applications such as spectroscopy, sensing, imaging, and drug
delivery [267-270]. Due to their high surface area, nanoparticles offer an attractive
platform for mass spectrometric enrichment strategies of peptides. Gold can form strong
bonds with soft ligands such as thiols, a property which is exploited in the stabilization
and derivatization of AuNPs, as well as in the field of self-assembled monolayers [271].
Thiols also have the ability to displace weaker-binding ligands from Au, a property which
is utilized in popular AuNP synthesis strategies [272]. Au-bound thiols can undergo thiol
exchange with each other, the extent of thiol exchange depending on concentrations, and
importantly, the chemical structure of the thiol ligands [273]. Much like ligand
displacement and thiol exchange in preparation of nanoparticles and self-assembled
monolayers, we tested the hypothesis that peptides containing thiols could displace
weakly-bound citrate ligands, and be subsequently purified by thiol exchange using a
small molecular weight thiol such as DTT. Unlike water-soluble PEG or carboxylate
alkylthiol AuNPs, citrate capped AuNP provide low-affinity ligands with similar
structure to peptides that could be displaced with thiol-containing peptides [274].
Our group developed a AuNP-based method for identifying protein S-nitrosation
sites, which relies on the natural affinity of thiols for gold [275]. In the original
publication the method was tested with a single purified protein. Here we use a mixture
of 5 purified proteins. Three recombinant proteins were used in the study: cystathionine
gamma-lyase (CSE), protein disulfide isomerase (PDI), and dual specificity phosphatase
12 (DUSP 12 or YVH1). Two proteins were commercially purchased: bovine serum
albumin (BSA) and lysozyme. This generates a considerably more complex sample,
however makes identification of individual peptides possible using post source decay
(PSD) MALDI sequencing. PSD sequencing does not use a collision chamber to
fragment peptides. As a result many peptides do not fragment well, preventing de-novo
sequencing.
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4.2 Materials
4.2.1 Reagents
Gold (III) chloride trihydrate (520918), bovine serum albumin (A-9647), lysozyme (L7651), α-cyano-4-hydroxycinnamic acid (476870) were purchased from Sigma-Aldrich.
DTT (100597) was purchased from MP Biomedicals. C18 Zip Tips® (ZTC18S096) were
purchased from Millipore. Sequencing grade trypsin (V511A) was purchased from
Promega. ZebaTM desalting columns (89882) were purchased from ThermoFisher.
Acetonitrile and 0.1% trifluoroacetic acid solution were mass spectrometry grade
reagents.

89

4.3 Methods
4.3.1 AuNP Synthesis
AuNPs were synthesized according to the protocol by Grabar et al. [276]. The synthesis
was scaled down to produce 250 mL of AuNPs. A 500 mL round-bottom flask was
cleaned with aqua regia (1:3 concentrated HNO3:HCl) and rinsed with Milli-Q water
before use. Gold (III) chloride trihydrate (HAuCl4•3H2O) was dissolved in Milli-Q water
to a concentration of 1 mM. 250 mL of this solution was refluxed with vigorous stirring
to ~100 °C. When the temperature stabilized, 25 mL of a 38.8 mM solution of trisodium
citrate dihydrate (Na3C5H5O7•2H2O) in Milli-Q water was very rapidly injected using a
syringe. A rapid colour change from yellow, to clear, and to dark red was observed.
Reflux and stirring was continued for 10 min after injection, the heat source was
removed, and the solution was stirred for another 15 min. The resulting colloidal solution
was cooled to room temperature and stored in a brown glass flask at 4 °C until usage. The
UV-vis spectrum of the resulting AuNP solution showed a λmax of 520 nm. Long-term
storage of AuNPs at 4 °C may be detrimental for AuNP stability, since precipitation was
observed at a later date.
4.3.2 Protein Purification and Digestion
Recombinant human YVH1 was purified by the Vacratsis group (University of Windsor)
according to the published protocol [277], and kindly donated for our experiments.
Recombinant PDI and CSE were purified from E. coli containing the appropriate
expression vector according to the detailed protocol by Faccenda et al. [185]. Bovine
serum albumin and lysozyme were each dissolved in 50 mM Tris-HCl, 1 mM CaCl2 pH
7.6. CSE, PDI, and YVH1 were each buffer-exchanged into 50 mM Tris-HCl, 1 mM
CaCl2 using ZebaTM Desalt Spin Columns. Each protein was trypsin-digested for 18 h at
37 °C while shaking, using a trypsin:protein ratio of 1:40 by mass (protein concentration
0.2 µg/µL). BSA, lysozyme, CSE, PDI, and hYVH1 were mixed in a 1:1:1:1:1 ratio after
digestion.
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4.3.3 Peptide Purification by AuNPs
500 uL of AuNPs were centrifuged at 16,000 g for 10 min and 450 µL of the supernatant
was removed to concentrate the AuNPs. 40 µg (0.2 µg/µL) of the unquenched tryptic
protein digest was added to the AuNPs. The digest was incubated with AuNPs for 1 h at
room temperature. The AuNPs were centrifuged at 16,000 g for 10 min. The supernatant
was removed and the AuNPs were resuspended in 500 µL of 10 mM sodium phosphate
buffer (pH 7.0) with sonication to redisperse aggregates. The AuNPs were centrifuged at
16,000 g for 10 min and the supernatant was removed. Washing with 500 µL of 10 mM
sodium phosphate buffer (pH 7.0) was repeated two more times. After the last wash 40
µL of 50 mM DTT was added to the AuNP pellet. The AuNPs were redispersed with
sonication, and incubated in DTT for 1 h. The AuNPs were centrifuged at 16,000 g for 15
min and the supernatant was removed for analysis.
4.3.4 Mass Spectrometry
The DTT elution was acidified with 20 µL 0.1% trifluoroacetic acid and purified with
Millipore C18 ZipTips®. 1 µL of sample was spotted with 1 µL of 10 mg/mL matrix
solution (α-cyano-4-hydroxycinnamic acid in 60% acetonitrile, 0.1% trifluoroacetic acid)
on a MALDI plate, and analyzed by an Applied Biosystems Voyager DE-Pro Mass
Spectrometer. Linear mode was used to acquire fingerprint spectra. The fingerprint and
PSD (post-source decay) spectra were manually compared to the masses predicted by
UCSF Protein Prospector (http://prospector.ucsf.edu).
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4.4 Results
4.4.1 Sulfur-Containing Peptide Enrichment by AuNPs
In the control digest, before AuNP purification six sulfur-containing peptides are
observed (Figure 4.4-1 and Table 4.4-1). Three of the peptides are thiols (cysteine
containing). A high baseline signal is observed in the control sample indicating a
complex mixture. After AuNP purification thirteen sulfur-containing peptides are
observed, including seven cysteine-containing peptides (Figure 4.4-2 and Table 4.4-2).
The baseline signal has considerably decreased (Figure 4.4-2) and sulfur-containing
peptides constitute a much larger proportion of the detected peptides versus the control.
Some non-sulfur peptides are still present after AuNP purification.
4.4.2 Additional MALDI-MS PDS Spectra
Individual MALDI-MS PSD spectra have been included in Appendix B.
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Figure 4.4-1 MALDI-MS spectrum of a tryptic digest of a mixture of 5 proteins: BSA,
CSE, lysozyme, PDI, and YVH1. Six sulfur-containing peptides were identified in the
sample.

Figure 4.4-2 MALDI-MS spectrum of a tryptic digest of a mixture of 5 proteins: BSA,
CSE, lysozyme, PDI, and YVH1, subject to sulfur enrichment by AuNPs. Thirteen
sulfur-containing peptides were identified in the sample.
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Table 4.4-1 Sulfur-containing peptides identified by MALDI-MS in a tryptic digest of a
mixture of 5 proteins; BSA, CSE, lysozyme, PDI, and YVH1.
Peptide Sequence

Observed Predicted Protein
Avg. m/z Avg. m/z

CVAFIGQAR

965.94

965.17

YVH1

MNEGFEWQLK

1282.84

1282.47

YVH1

GSHMASMTGGEEMGR

1537.17

1538.73

PDI

LGSFNWYGEQCSCGR

1706.28

1707.89

YVH1

IKPHLMSQELPEDWDKQPVK

2419.36

2419.82

PDI

GSPEFMLEAPGPSDGCELSNPSASR

2536.16

2536.77

YVH1
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Table 4.4-2 Sulfur-containing peptides identified by MALDI-MS after AuNP-based
purification of a tryptic digest of a mixture of 5 proteins: BSA, CSE, lysozyme, PDI, and
YVH1.
Peptide Sequence

Protein

Observed

Predicted

Avg. m/z

Avg. m/z

CRRSLFR

937.96

938.15

YVH1

CVAFIGQAR

966.36

965.17

YVH1

MTPSSMLTTGR

1183.16

1182.41

YVH1

MNEGFEWQLK

1283.31

1282.47

YVH1

WWCNDGRTPGSR

1436.16

1435.57

Lysozyme

GSHMASMTGGEEMGR

1537.41

1538.73

PDI

IVSDGNGMNAWVAWR

1677.65

1676.91

Lysozyme

LGSFNWYGEQCSCGR

1708.41

1707.89

YVH1

KIVSDGNGMNAWVAWR

1805.44

1805.08

Lysozyme

RPCFSALTPDETYVPK

1825.68

1825.11

BSA

IKPHLMSQELPEDWDKQPVK

2419.85

2419.82

PDI

GSPEFMLEAPGPSDGCELSNPSASR

2536.71

2536.77

YVH1

YMNGHSDVVMGLVSVNCESLHNR

2563.19

2562.92

CSE
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4.5 Discussion
4.5.1 Spectra Interpretation
The proteins used in this study have various abundances of sulfur-containing residues,
ranging from 12 sulfur-containing residues in lysozyme to 40 sulfur-containing residues
in BSA, 35 of which are thiols (cysteines). MALDI-TOF-MS remains a qualitative
technique where many factors such as abundance, ionization efficiency, and ion
suppression due to sample composition affect which peptides are observed in the MS
spectra. As a result only six sulfur-containing peptides are observed in the five protein
mixture, which increases to thirteen sulfur-containing peptides after AuNP purification.
The proportion of sulfur-containing peptides is greatly improved after AuNP purification
as the majority of non-sulfur peptides are removed from the spectra.
4.5.2 Interaction of Peptides and AuNPs
Free thiols can bind to Au through gold-thiolate bonding. Disulfides are generally broken
upon binding to the Au surface, resulting in a gold-thiolate bond [278, 279]. Thioethers
cannot form gold-thiolate bonds but are adsorbed intact on Au surfaces [279-281].
Although Au binds preferentially to thiols, AuNPs can be stabilized using citrate, and Au
has some affinity for the carboxyl groups in citrate. Since peptides are large, complex,
molecules, with multiple charges, other functional groups likely contribute to binding to
AuNPs. The binding of peptides to Au is likely not as strong as for alkyl-thiols since
alkyl thiols are further stabilized with hydrophobic interactions from alkyl chains, which
are not present in peptides. Low binding affinity is beneficial for allowing disulfide
exchange with small molecular weight thiols like DTT. However, the binding may not
provide high enough affinity to purify only thiol-containing peptides. If strong Aupeptide binding was occurring one might expect only cysteine-containing peptides
(thiols) to be purified, and not methionines (thioethers). However, purification of
thioethers may be useful for studies where alkylating agents like iodoacetamide and Nethylmaleimide are used, which generate a thioether linkage.
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4.6 Conclusions
AuNPs were used to purify sulfur-containing peptides from a mixed tryptic digest of 5
purified proteins: BSA, CSE, lysozyme, PDI, and YVH1. Using MALDI-MS analysis six
sulfur-containing peptides were identified before AuNP enrichment, and thirteen after
AuNP enrichment. Importantly, the proportion of sulfur-containing peptides in the
spectra increases after AuNP purification. Both cysteines and methionines are purified by
AuNPs, however non-sulfur peptides are not fully removed. The results demonstrate
AuNPs may be used for sample purification in mass spectrometric studies of sulfurcontaining proteins.
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CHAPTER 5

DEVELOPMENT OF NO-RELEASING MATERIALS FOR WOUND HEALING
APPLICATIONS
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5.1 Introduction
NO is an important mediator of wound healing, and NO-releasing materials have the
potential to be used as therapeutic agents to improve wound healing [206, 282], both in
disease states and healthy tissues. In this chapter we aimed to develop NO-releasing
wound dressings to improve cutaneous wound healing. Two different designs of wound
dressings have been proposed. In the first design the chemistry of NO release is due to
the denitrosation of small molecular weight S-nitrosothiols by gold nanoparticles
(AuNPs). In the second design the NO release is due to the reduction of NO2- ions to NO
by copper. The proposed S-nitrosothiol based design is activated by a pressure-sensitive
membrane. Upon breaking a pressure-sensitive membrane, mixing of the two solutions
would occur, and initiate the reaction of S-nitrosothiols and metals, which would release
NO at the wound site (Figure 5.1-1). It has been proposed AuNPs denitrosate Snitrosothiols by forming a gold-sulfur bond and releasing NO in the process (Eq. 5.1-1)
[283, 284].

The second design features a chitosan polymer doped with either CuNPs or copper ions.
Cu(I) can reduce NO2- to NO (Eq. 5.1-2) [285], and can also denitrosate S-nitrosothiols to
generate NO (Eq. 5.1-3) [286, 287]. A large number of studies indicate that chitosan has
inherent antimicrobial, and wound healing abilities [288]. In this design chitosan is not an
inert compound for suspending copper, but is also expected to improve the wound
healing process.

Chitin is the second most abundant natural polymer after cellulose [289]. Chitin is
a derivative of glucose (N-acetyl-β-D-glucosamine) synthesized by many organisms, and
forms the exoskeleton of arthropods (eg. insects, crustaceans), as well as the cell walls of
fungi and yeast. Treatment of purified chitin with NaOH causes deacetylation of chitin
forming chitosan (D-glucosamine) (Figure 5.1-2). Different types of chitosan are
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characterized by their degree of deacetylation (DD), distribution of acetyl groups on the
main chain, and the molecular weight. The amine groups on chitosan allow chitosan to be
soluble in acidic solutions, although the exact solubility properties depend strongly on
how the chitosan was purified from chitin [289]. Due to the abundance of amine groups
in chitosan, chitosan has an ability to chelate metal ions. For divalent ions chitosan shows
the highest selectivity towards Cu2+, while for trivalent ions chitosan shows highest
selectivity towards Eu3+ and Nd3+ [290]. Since chitosan is a cationic polymer it could be
also used to absorb and remove anionic dyes from solution [291]. Numerous studies have
used chitosan to remove metal ions, and dyes from waste water [291, 292].
Chitosan has numerous possible biomedical applications due to the fact it’s a
biodegradable and non-toxic polymer with intrinsic wound-healing properties. Chitosan
also has intrinsic antimicrobial and antifungal properties [293]. The antimicrobial
properties of chitosan are related to its DD, and higher DD chitosan produces stronger
antimicrobial effects [294]. Although the exact mechanism is not known, it has been
theorized that the positive charge on chitosan destabilizes and permeates the cell
membrane of gram-negative bacteria [288, 293]. In gram positive bacteria chitosan may
chelate multivalent cations which stabilize the cell wall [293]. Chitosan has been shown
to promote blood clot formation, and commercial chitosan-based wound dressings have
been shown to be more effective at stopping hemorrhage than standard cotton gauze in
animal studies [295]. At least one chitosan-containing bandage has been commercialized
(HemCon®) and has been tested as a hemostatic by EMS services [296] and the US
Army [297]. A study by Gopal et al. in 2014 tested a solution of copper nanoparticles and
chitosan dissolved in 0.1% acetic acid in an animal model of wound healing [298]. The
solution showed improved wound healing compared to chitosan without copper
nanoparticles, and the control. However, the control was 0.1% acetic acid solution and no
untreated control was shown. A study by Khan et al. showed acetic acid chitosan films
caused skin irritation, while lactic acid chitosan films did not [299].
Studies show that copper has antimicrobial [300, 301], and wound healing
properties [302-304]. Copper is biocidal, and far less likely to produce adverse skin
reactions than silver. In recent years, the rise of antibiotic-resistant bacteria has led to
100

renewed interest in the antimicrobial properties of copper [300, 301]. The use of copper
touch surfaces in hospitals may help the spread of bacteria. The wound healing effects of
copper are less widely-studied. In 2008 Borkow et al. hypothesized that persistence of
chronic wounds may be caused by low local levels of copper [303]. Copper is an essential
trace element, and many cellular processes important in wound healing are copperdependent. Borkow et al. tested copper oxide impregnated wound dressing in diabetic
mouse, and showed copper oxide dressings improved wound healing [302]. The
mechanism of action was hypothesized to be generation of H2O2 and hydroxyl radicals
through redox cycling between CuO and Cu2O. Analysis by real-time PCR and
histochemistry showed numerous proangiogenic growth factors were upregulated with
the use of copper oxide wound dressings.
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Figure 5.1-1 Proposed design of an S-nitrosothiol based NO-releasing wound dressing.
Upon breaking of the disruptable membrane S-nitrosothiol solution and Ag- or Aucomposite material would come in contact. Reaction of Ag or Au with S-nitrosothiols
will cause denitrosation of S-nitrosothiols and NO release through the gas permeable
membrane.
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Figure 5.1-2 (A) Chemical structure of chitin. (B) Chemical structure of chitosan.
Treatment of chitin with NaOH causes partial deacetylation resulting in chitosan. 50%
deacetylation is shown in this example.

102

5.2 Materials
5.2.1 Reagents
Gold (III) chloride trihydrate (520918), Sephadex® G-75 (G-75-120), cellulose (C8002),
tetraethyl orthosilicate (TEOS) (86578), triethyl phosphate (TEP) (538728), Ca(NO3)2
(20-296-7), AgNO3 (209139), diethylenetriaminepentaacetic acid (DTPA) (D6518),
hydrazine (225819), ethylene glycol (102466), NaNO2 (237213), lactic acid (252476),
CuCl (212946), Minimum Essential Medium (MEM), reduced glutathione were
purchased from Sigma-Aldrich. Polydimethylsiloxane (PDMS) Sylgard® 184 Silicone
Elastomer Kit was purchased from Dow Corning. Chitosan (AZ-78-6101) was purchased
from Dungeness Environmental Solutions. Ethylene glycol diglycidyl ether (EGDE)
(01479-100) was purchased from Polysciences. Gibco® Fetal Bovine Serum was
purchased ThermoFisher.
5.2.2 Materials
Septa-sealed vials (Supelco 27533) were purchased from Sigma-Aldrich. 1 mL syringes
(309659) were purchased from BD. Polystyrene columns (29920) were purchased from
Fisher Scientific.
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5.3 Methods
5.3.1 AuNP Synthesis
AuNPs were synthesized according to the protocol by Grabar et al. [276]. The synthesis
was scaled down to produce 250 mL of AuNPs. A 500 mL round-bottom flask was
cleaned with aqua regia (1:3 concentrated HNO3:HCl) and rinsed with Milli-Q water
before use. Gold (III) chloride trihydrate (HAuCl4•3H2O) (Sigma Aldrich) was dissolved
in Milli-Q water to a concentration of 1 mM. 250 mL of this solution was refluxed with
vigorous stirring to ~100 °C. When the temperature stabilized, 25 mL of a 38.8 mM
solution of trisodium citrate dihydrate (Na3C5H5O7•2H2O) (Sigma Aldrich) in Milli-Q
water was very rapidly injected using a syringe. A rapid colour change from yellow, to
clear, and to dark red was observed. Reflux and stirring was continued for 10 min after
injection, the heat source was removed, and the solution was stirred for another 15 min.
The resulting colloidal solution was cooled to room temperature and stored in a brown
glass flask at 4 °C until usage. The UV-VIS spectrum of the resulting AuNP solution
showed a λmax of 520 nm. Long-term storage of AuNPs at 4 °C may be detrimental for
AuNP stability, since precipitation was observed at a later date.
5.3.2 AuNP-PDMS
0.2 mL of PDMS mixture was cast directly in vials. A ratio of 0.04 curing agent to
monomer base was used. This was previously determined by Adam Faccenda to be the
optimum for AuNP synthesis on PDMS surfaces. PDMS was cured for 40 minutes at 70
°C. The vials were cooled to room temperature. 0.5 mL of a solution containing 10 mM
HAuCl4 and 5 mM citrate was added to each vial. The vial was placed on a shaker at
room temperature for 3 h. The vial was removed and any gold flakes were pipetted off
the surface before the solution was removed. The resulting AuNP-PDMS was washed
with H2O three times. Control vials were not treated with the HAuCl4 and citrate solution.
5.3.3 AuNP-G75 Sephadex
PBS was added to G-75 Sephadex to make a slurry. An equal volume of AuNPs was
added to the slurry, and mixed. The slurry was poured into a chromatography column,
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and washed with PBS to remove unbound AuNPs. 100 µL of the slurry was taken out of
the column and added to each septa-sealed vial. Control G-75 did not contain AuNPs.
5.3.4 AuNP-Cellulose
1 g of α-cellulose was added to 40 mL of AuNPs. The mixture was placed on a nutating
mixer. Excess AuNPs were removed as in the AuNP-G75 Sephadex protocol. 150 µL of
the cellulose was added to each septa-sealed vial.
5.3.5 AuNP-Gauze
A ~1 x 1 inch piece of gauze was placed in a petri dish. AuNPs were added, and the
gauze was soaked overnight. The excess AuNPs were removed, and the AuNP-gauze was
washed with H2O until no more AuNPs eluted from the gauze into the H2O (no red
colour). The gauze was dried at ~50 °C. The gauze was compared by weight to a piece of
control gauze. Pieces with approximately equal weight (~0.5 x 1 cm for AuNP and ~0.5 x
1.5 cm for control) were cut and placed inside septa-sealed vials.
5.3.6 AuNP-Glass Synthesis
AuNP doped glass was synthesized according to the sol-gel protocol published by
Lusvardi et al. [305]. 3.542 g of Ca(NO3)2•4H2O and 0.788 g of HAuCl4•3H2O was
dissolved in 12.96 mL of HCl (0.0091 M). 17.84 mL TEOS and 1.71 mL of TEP were
added to 40 mL of ethanol. The Ca/Au solution was added to the TEOS/TEP solution and
stirred well. The stirred solution was transferred to an airtight Teflon container and kept
at room temperature for 24 h. The gel was transferred to an open crucible and heated for
3 h at 600 °C. The control glass was prepared the same way except without the addition
of HAuCl4•3H2O. 5 mg of AuNP-glass or control glass was placed in each septa-sealed
vial for NO measurements.
5.3.7 Ag2S-Paper
Filter paper was soaked twice in a methanol solution saturated with AgNO3. Filter paper
was then rinsed in methanol solution three times, and air dried at room temperature. 10
mM Na2S solution was added to the filter paper to form Ag2S. The filter paper was rinsed
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in H2O solution three times, and air dried at room temperature. 9 mg of Ag2S-paper or
control paper was used per vial for NO measurements.
5.3.8 NO Measurements from AuNP and Ag Composites
Vials containing the AuNP-composite and controls were sealed and degassed with argon
for 7 minutes each. Sievers Nitric Oxide Analyzer (NOA 280i) was set up using the
standard NO2- measurement mode and standardized with NO2- according to manufacturer
protocol. GSNO was dissolved in 100 µM DTPA. 200 µL of GSNO was added to a
degassed vial, the vial was incubated 10 minutes, and 1 mL of the headspace was injected
into the reaction chamber. Separate syringes were used for GSNO and headspace
injections. When gas from the vial headspace was injected into the NOA reaction
chamber, it was injected into the reaction chamber headspace, and the syringe needle did
not touch the solution inside.
Each vial was timed exactly 10 minutes between injection of GSNO into vials and
measurement of vial headspace. The addition of GSNO to individual vials was done in 2
min intervals, and the subsequent injection of NO into the NOA was done in 2 min
intervals (exactly 10 minutes later). By the 5th injection of GSNO, the injections of
GSNO and NO will start overlapping. For simplicity and more accurate timing, the
incubations and measurements were done in sets of 4 or 5 samples, so the injections of
NO and GSNO did not overlap.
5.3.9 CuNP Synthesis
CuNPs were synthesized according to protocol by Zhu et al. [306]. 20 mL of N2H4 and
NaOH in ethylene glycol was added to 20 mL of 0.1 M CuSO4 in ethylene glycol while
stirring. The molar ratio of N2H4 to CuSO4 was 1.5, while the molar ratio of NaOH to
CuSO4 was 0.05. The solution was irradiated in a household microwave oven and cycled
18 s on, 12 s off, for 3 min. Nanoparticles were isolated by centrifugation and washed
with anhydrous ethanol.
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5.3.10 Chitosan and CuNP-Chitosan Film Preparation
To prepare chitosan films, 0.2 g of chitosan was added to 9.6 mL H2O while stirring.
Stirring was continued for 5 minutes. For CuNP-chitosan 10 mg of solid CuNPs were
added. Stirring was continued for 5 minutes. 200 µL of acetic acid or lactic acid was
added to the chitosan dropwise while stirring. Stirring was continued for 1 h. The CuNPs
may slowly disperse and dissolve, however the process will not occur to completion.
Chitosan was poured into weighing boats and dried for at least 48 h. Drying time will
vary depending on temperature and humidity. Control chitosan and CuNP-chitosan, used
for NO release experiments examining the effect of the addition of thiol to the films, was
prepared using this method. Later an improved method was used (vide infra). The
amounts may be scaled up depending on how much chitosan one wants to make. 0.2 g of
chitosan in ~10 mL results in a 2% chitosan mixture. The volume added to weighting
boats may be changed to control film thickness.
5.3.11 Cu-Chitosan Film Preparation, Glucose-Chitosan Film Preparation, and
Improved CuNP-Chitosan Film Preparation
An improved protocol was used to prepare CuNP-chitosan films in order to reduce time
and improve CuNP dispersion. To prepare chitosan films, 0.2 g of chitosan was added to
9.6 mL of H2O while stirring. Stirring was continued for 5 minutes. The solution was
now transferred from a beaker to a falcon tube. 10 mg of solid CuNPs was added to the
falcon tube, and the falcon tube was sonicated in a water bath sonicator to disperse the
CuNPs. Afterwards, the solution was poured back into the same beaker, and stirring was
continued. 200 µL of lactic acid was added to the chitosan dropwise while stirring.
Stirring was continued for 5 minutes. 10 mL of 0.33 M glucose solution was now added,
and stirred for 5 minutes. 5 mL of the resulting mixture was poured into each weighing
boat, and dried for at least 48 h.
The amount of copper salt to be added to chitosan was calculated to be equivalent
in mol Cu to 10 mg of CuNPs. For CuCl it was 0.0156 g, for Cu2O it was 0.0112 g, etc.
To prepare chitosan, 0.2 g of chitosan was added to 9.6 mL of H2O while stirring. Stirring
was continued for 5 minutes. Cu was added to the solution and stirring was continued for
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5 min. 200 µL of lactic acid was added to the chitosan dropwise while stirring. Stirring
was continued for 5 minutes. 10 mL of 0.33 M glucose solution was now added, and
stirred for 5 minutes. 5 mL of the resulting mixture was poured into each weighing boat.
When comparing chitosan with or without glucose, 10 mL of H2O was added instead of
0.33 M glucose to keep the % of chitosan the same. Using this protocol the resulting
chitosan concentration in the slurry was 1%, although the concentration can be easily
adjusted if so desired. 6 mL of the resulting mixture was poured into each weighing boat,
and dried for at least 48 h.
5.3.12 Cross-linked Chitosan Film Preparation
Chitosan films were cross-linked by placing them in 1% EGDE solution in methanol on a
shaker for 18 h. Films were washed with methanol to remove excess EGDE, and air
dried.
5.3.13 Solution Concentrations for NO Measurements of Chitosan and CuNPChitosan, With, and Without GSH
In the first experiment, 7 mg of chitosan, or CuNP-chitosan was placed in septa-sealed
vials and degassed with argon for 5 minutes. 100 µL of 10 mM sodium phosphate buffer
pH 7.0 and 100 µL of 100 µM NO2- was injected into vials during measurements. 100 µL
of GSH in 10 mM sodium phosphate buffer pH 7.0 was used for testing CuNP-chitosan
in the presence of thiol, instead of buffer alone Time between injection of NO2- and NO
measurement was 10 minutes.
In the second experiment the amount of CuNP-chitosan was reduced to 2.5 mg.
100 µL of 10 mM sodium phosphate buffer pH 7.0 and 100 µL of 50 µM NO2- was
injected into vials during measurements. 100 µL of 200 µM GSH in 10 mM sodium
phosphate buffer pH 7.0 was used for the CuNP-chitosan in testing presence of thiol,
instead of buffer alone.
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5.3.14 Solution Concentrations for NO Measurements in the Comparison of
Different Sources of Cu in Cu-Glucose-Chitosan
0.5 x 0.5 cm chitosan squares were cut, placed in septa-sealed vials, and degassed with
argon for 5 minutes. 100 µL of minimum essential media (MEM) supplemented with
fetal bovine serum (FBS) and 100 µL 50 µM NO2- was injected into the vials. Time
between injection of NO2- and NO measurement was 15 minutes.
5.3.15 Solution Concentrations for NO Measurements Determining the Effect
of Glucose on Cu-Chitosan
0.6 x 0.6 cm chitosan squares were cut, placed in septa-sealed vials, and degassed with
argon for 5 minutes. 200 µL of 10 µM NO2- in PBS was injected into vials. Time between
injection of NO2- and NO measurement was 15 minutes.
5.3.16 Solution Concentrations for NO Measurements of Cross-linked Chitosan
and Cu-Chitosan
0.5 x 0.5 cm chitosan squares were cut, placed in septa-sealed vials, and degassed with
argon for 5 minutes. 200 µL of NO2- in PBS and 100 µL of 2 g/L glucose in PBS was
injected into vials. Time between injection of NO2- and NO measurement was 15
minutes.
5.3.17 NO Measurements from Chitosan and Cu-Chitosan Films
Vials containing the Cu-chitosan and control chitosan were sealed and degassed with
argon for 5 minutes each. Sievers Nitric Oxide Analyzer (NOA 280i) was set up using the
standard NO2- measurement mode and standardized with NO2- according to manufacturer
protocol. NO2- in PBS was injected into the degassed vials, and vials were incubated 10
minutes or 15 minutes depending on the experiment. 1 mL of the headspace was injected
into the reaction chamber.
Separate syringes were used for NO2- and headspace injections. When aspirating
the gas from the vial headspace one must be extremely careful not to touch the NO2solution inside. If the syringe comes in contact with NO2-, the NO2- will be converted to
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NO in the NOA reaction chamber and give a false signal. When gas from the vial
headspace was injected into the NOA reaction chamber, it was injected into the reaction
chamber headspace, and the syringe needle did not touch the solution inside. Even when
following this protocol previous contact with NO2- may produce a false signal.
Each vial was timed exactly 10 minutes between injection of NO2- into vials and
measurement of vial headspace. The addition of NO2- to individual vials was done in 2
min intervals, and the subsequent injection of NO into the NOA was done in 2 min
intervals (exactly 10 minutes later). By the 5th injection of NO2-, the injections of NO2and NO will start overlapping. For simplicity and more accurate timing, the incubations
and measurements were done in sets of 4 or 5 samples, so the injections of NO2- and NO
did not overlap. When following the protocol with 15 minutes between injections sets of
6 samples were used.
Different types of samples were measured first, and subsequently replicates were
measured. For example samples were injected in the order: control, copper, control,
copper, control, copper, and not control, control, control, copper, copper, copper. This
was done in case contamination of the syringe needle occurred, it would be easier to spot,
and less likely to be mistaken for genuine NO release.
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5.4 Results
5.4.1 NO Release from GSNO by Au and Ag Composites
All the AuNP and Ag composites tested (AuNP-PDMS, AuNP-G75, AuNP-Cellulose,
AuNP-Gauze, AuNP-Glass, Ag2S-Paper) were able to denitrosate S-nitrosothiols,
producing gaseous NO (Figures 5.4.1-1 to 5.4.1-6). These results support the previouslydescribed denitrosation mechanism of S-nitrosothiols by AuNPs [283]. It is likely Ag can
denitrosate S-nitrosothiols using a similar mechanism as Cu or Au. All the materials
tested also displayed at least some de-nitrosation without any Au or Ag present. This is
most likely due to metal ion contamination. However, the presence of AuNPs or Ag does
provide significant increase in released NO.
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Figure 5.4.1-1 NO release from GSNO by AuNP-PDMS compared to control PDMS. 1
mL of headspace gas was measured 10 min after the addition of GSNO to a septa-sealed
vial.
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Figure 5.4.1-2 NO release from GSNO by AuNP-G75 Sephadex compared to control
G75 Sephadex. 1 mL of headspace gas was measured 10 min after the addition of GSNO
to a septa-sealed vial.
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Figure 5.4.1-3 NO release from GSNO by AuNP-cellulose compared to control
cellulose. 1 mL of headspace gas was measured 10 min after the addition of GSNO to a
septa-sealed vial.
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Figure 5.4.1-4 NO release from GSNO by AuNP-gauze compared to control gauze. 1 mL
of headspace gas was measured 10 min after the addition of GSNO to a septa-sealed vial.
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Figure 5.4.1-5 NO release from GSNO by AuNP-glass compared to control glass. 1 mL
of headspace gas was measured 10 min after the addition of GSNO to a septa-sealed vial.
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Figure 5.4.1-6 NO release from GSNO by Ag2S-paper compared to control paper. 1 mL
of headspace gas was measured 10 min after the addition of GSNO to a septa-sealed vial.
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5.4.2 NO Release from NO2- by Cu-Chitosan
Chitosan embedded with CuNPs was able to generate NO from NO2- (Figure 5.4.2-1).
Copper is expected to be oxidized in this reaction from Cu(I) to Cu(II). GSH was added
to the chitosan to test whether it could reduce Cu(II) back to Cu(I). In an experiment with
10 mg chitosan there was no significant difference between copper and copper with GSH
(Figure 5.4.2-1). When the amount of chitosan was reduced to 2.5 mg the addition of
GSH did increase NO release (Figure 5.4.2-2), although the total NO released was much
lower.
Different sources of copper were tested to determine whether they can replace
microwave synthesized CuNPs. In this experiment, glucose was added to the chitosan
mixture before casting in order to attempt to improve the physical properties of the films.
Minimum Essential Medium (MEM) supplemented with fetal bovine serum (FBS) was
added to chitosan during NO release experiments to test whether cell culture media
would interfere with potential cell culture experiments. It was found different copper
sources (CuNP, CuSO4, CuCl, Cu2O) can facilitate release of NO from NO2- in chitosan
(Figure 5.4.2-3). This is likely due to the chitosan being supplemented with glucose.
When using a CuCl as a source of copper, it was determined the addition of glucose to
the chitosan before casting a film was required for NO release (Figure 5.4.2-4).
Chemical cross-linking was used to try to improve the physical properties of the
chitosan films and prevent cracking of the film after drying. It was found cross-linking
prevented NO release by the Cu-chitosan films (Figure 5.4.2-5). In this experiment
glucose was added to chitosan films alongside NO2- during NO measurements.
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Figure 5.4.2-1 NO release from NO2- by 10 mg CuNP-chitosan with and without reduced
glutathione (GSH). 1 mL of headspace gas was measured 10 min after 100 µL of pH 7.0
10 mM PO43- buffer (with or without GSH) and 100 µL of 100 µM NO2- was injected into
a septa-sealed vial. Error bars represent standard error (n=3).
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Figure 5.4.2-2 NO release from NO2- by 2.5 mg CuNP-chitosan with and without
reduced glutathione (GSH). 1 mL of headspace gas was measured 10 min after 100 µL of
pH 7.0 10 mM PO43- buffer (with or without GSH) and 100 µL of 50 µM NO2- was
injected into a septa-sealed vial. Error bars represent standard error (n=3).
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Figure 5.4.2-3 NO release from NO2- by Cu-glucose-chitosan prepared using different
sources of copper in the presence of minimum essential media (MEM) supplemented
with fetal bovine serum (FBS). 1 mL of headspace gas was measured 15 min after 100 µL
of MEM and 100 µL 50 µM NO2- was injected into a septa-sealed vial. Error bars
represent standard error (n=3).
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Figure 5.4.2-4 Effect of glucose and CuCl on NO release from NO2- by chitosan. CuCl
and glucose were incorporated into chitosan films. 1 mL of headspace gas was measured
15 min after 200 µL of 10 µM NO2- in PBS was injected into a septa-sealed vial. Error
bars represent standard error (n=3).
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Figure 5.4.2-5 Effect of EGDE cross-linking of chitosan on NO release from NO2-. 1 mL
of headspace gas was measured 15 min after 200 µL of NO2- in PBS and 100 µL of 2 g/L
glucose in PBS was injected into a septa-sealed vial. Error bars represent standard error
(n=3).
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5.5 Discussion
5.5.1 NO Release from GSNO by AuNP and Ag Composites
All of our AuNP and Ag composites tested were able to denitrosate S-nitrosothiols, and
produce NO since they contain either Au or Ag. The presence of AuNPs or Ag does
increase the NO release versus the control materials. The control materials did facilitate
some NO release, which is likely due to trace metal contamination. PDMS uses a
proprietary metal catalyst to cure the PMDS polymer, which can likely denitrosate Snitrosothiols. Other materials used are likely contaminated with trace metals. It is also
possible the vials used were contaminated with trace metals. The relative NO release
cannot be reliably compared, since the amount of Au or Ag in each material has not been
quantified.
5.5.2 Proposed SNO-Based NO-Releasing Wound Dressing
The proposed design of the wound dressing uses S-nitrosothiols as a source of NO. While
the chemistry of S-nitrosothiols is convenient, this is problematic for storage of the
wound dressing, as S-nitrosothiols are not stable at high temperatures. During use of the
proposed wound dressing, the ambient temperatures could also affect NO release. Snitrosothiols are also unstable when exposed to light, and the external packaging would
require the S-nitrosothiols to be protected from light. The proposed design uses gold to
denitrosate S-nitrosothiols. Copper or silver could replace gold, which is an expensive
material. The kinetics of NO release may be changed by changing the amount of metal in
the composites. Although the kinetics of NO release may be prolonged, it is unknown if
they could be prolonged for the extended periods of time that are required for wound
healing.
The design of the wound dressing itself introduces packaging challenges. The
dressing design requires NO to diffuse through a gas-permeable membrane, and then
through a traditional wound dressing, such as cotton gauze, to reach the site. The amount
of NO actually released at the wound site would also have to be tested if a prototype was
constructed. Furthermore, effective bandages allow gas-exchange at the wound site [307].
This could be a challenge due to the proposed design. The multi-layered design might not
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effectively facilitate gas-exchange at the wound site. To facilitate gas exchange, a
permeable membrane could be incorporated on both sides of the wound dressing, the side
facing the wound and the side facing away. This would facilitate more gas exchange but
also cause NO loss to the external environment.
5.5.3 NO Release from NO2- by Cu-Chitosan Films
The Cu-chitosan films were able to release NO from NO2-, which is a salt, and more
stable than S-nitrosothiols. During our initial experiments, CuNPs were used as the
source of copper. CuNPs were synthesized by microwave synthesis [306] and added to
the chitosan films. The CuNPs used are uncapped, meaning they have no capping agent
like citrate in classic AuNPs. The copper in the CuNPs is in the Cu(0) oxidation state
after synthesis. After the addition of acetic acid or lactic acid to CuNP-chitosan solution,
the solution turns green indicating oxidation of the copper. The CuNPs do not fully
dissolve, and when cast into a film do not disperse evenly, resulting in an uneven
distribution of CuNPs in the film. Sonication improves this only to a certain extent.
Since the copper partially oxidizes during casting of the films, it was tested
whether the addition of thiols can increase the NO release by reducing Cu(II) to Cu(I). At
high amounts of chitosan (10 mg) the addition of GSH did not significantly increase the
amount of NO release (Figure 5.4.2-1). However, at lower amounts of chitosan (2.5 mg),
the amount of reduced copper in the film becomes limiting and the addition of GSH does
increase NO release (Figure 5.4.2-2). When glucose is cast with chitosan, other sources
of copper can be used to generate NO from NO2- (Figure 5.4.2-3). Glucose is a reducing
sugar and can reduce Cu(II) to Cu(I), however it was incorporated into the film rather
than added with NO2-. The reduction of Cu(II) by glucose is the basis of Benedict's
reagent, a reagent used in a colourimetric test for reducing sugars. When using copper
salts like CuCl, copper was oxidized from Cu(I) to Cu(II) when incorporated into
chitosan films, and glucose was required for NO release (Figure 5.4.2-4).
5.5.4 Physical Properties of Cu-Chitosan Films
It was tested whether lactic acid can replace acetic acid for making chitosan films. Lactic
acid is expected to be more biocompatible than acetic acid [299]. During mixing of a
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chitosan solution, the acid is used to protonate the amino groups on chitosan and increase
the solubility of chitosan in solution before casting of the film. The specific acid used for
mixing the chitosan slurry is therefore interchangeable. When performing NO release
experiments it is important that NO2- is added to chitosan in a buffered solution, since
residual acid can reduce NO2- to NO. After casting of the chitosan slurry, the water
evaporates to form a chitosan film. Prolonged evaporation results in a film that is
extremely brittle. The addition of glucose allows the film to be soft for a longer period of
time; however the film will eventually become brittle with prolonged drying. The
browning reaction of glucose is also observed when drying the chitosan films. When
placed in water the chitosan films swell and break apart. Chemical cross-linking was
therefore used to try to improve the physical properties of the films, and prevent the films
from breaking apart. Ethylene glycol diglycidyl ether (EGDE) was used as the crosslinker, however cross-linking prevented NO release from chitosan films (Figure 5.4.2-5).
Chemical cross-linking may also alter the chemical and biological properties of chitosan
in an undesired way.
5.5.5 Proposed Design of Chitosan-Based NO-Releasing Wound Dressing
The proposed NO releasing chitosan-based bandage combines therapeutic effects from
chitosan, copper, and NO release. In this design the chitosan can be in contact with the
wound, and does not require complex packaging unlike our previous AuNP and Ag based
design. The use of chitosan also allows for gas exchange at the wound site. The use of
copper allows two pathways for NO release, the reduction of NO2- to NO, and the denitrosation of S-nitrosothiols. The copper may be able to react with native NO2- and Snitrosothiols to produce NO. Additional NO2- may also be applied to the wound dressing,
perhaps between the chitosan film, and an adhesive backing. Since the use of copper salts
required the incorporation of glucose into the chitosan films, CuNPs may be the best
copper source. Incorporating large amount of glucose, to reduce Cu(II), would likely be
detrimental to wound healing. However, thiols and glucose present in biological fluids
may provide a pathway for the regeneration of Cu(I) from Cu(II).
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5.5.6 Future Directions
In this work we studied the release of NO from copper-chitosan films in an endpoint
manner. The next step is to study the kinetics of NO release, and determine how much
NO the copper-chitosan films release over time. This would also help optimize the
chemical composition of the films. Ultimately, to test the efficacy of the proposed wound
healing dressings animal studies are required.
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5.6 Conclusions
In this chapter we sought to develop NO-releasing wound dressings that may be used to
improve wound healing. The first wound dressing design is based on the denitrosation of
S-nitrosothiols by gold or silver composites. The chemistry of S-nitrosothiols is
convenient; however this design produces packaging challenges. The second design uses
chitosan embedded with copper, which can reduce NO2- to NO, as well as denitrosate Snitrosothiols. The use of chitosan and NO2- eliminates the packaging challenges present in
the first design. Our experiments show chitosan films embedded with copper are effective
at reducing NO2- to NO. Although our therapeutic agent is NO, numerous studies show
that the use of chitosan or copper alone can improve wound healing in animal models.
NO-releasing copper-chitosan may be used as a wound dressing to improve wound
healing.
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CHAPTER 6

GENERAL DISCUSSION
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6.1 Discussion and Perspectives
The discovery of NO as a gasotransmitter in the late 1980’s has resulted not only in
discovery of an important biological pathway, but the establishment of a whole new field
of biological signaling. One of the major recent discoveries in the field of gaseous
signaling is H2S signaling. Many similarities between NO and H2S exist: biological
effects in the cardiovascular and nervous systems, interaction with biomolecules through
cysteine residues and heme iron, complex chemistry due to oxidation by O2, and potential
challenges when performing in vivo measurements. The study of gasotransmitters, like
NO and H2S, requires a strong understanding of their underlying chemistry. The overestimation of H2S concentrations in biological samples highlights this issue. It also
highlights the need for detailed understanding of analytical techniques used to detect H2S,
and the need for improved H2S detection methods. Driven by the need for accurate and
specific methods for detecting H2S, in Chapter 2 we developed a simple and specific
assay for H2S gas. This assay requires no specialized equipment, and provides researchers
an additional tool for studying H2S.
Similarly to S-nitrosation by NO, H2S can modify cysteine residues by Ssulfuration, affecting protein functions. In Chapter 3 we investigated the reported Ssulfuration of the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Our work on GAPDH S-sulfuration provides more insights into how H2S may
modify GAPDH cysteine residues, and in-turn affect GAPDH enzymatic activity.
Although our work was performed in vitro, it provides researchers clues about what could
be potentially occurring in vivo. We also demonstrate the importance of the initial
cysteine redox state of an enzyme, which will affect the response to gasotransmitters like
NO and H2S, highlighting the importance of basic biochemistry in studying
gasotransmitters.
Mass spectrometry is an extremely powerful and versatile tool for studying
protein

post-translational

modifications,

including

modifications

induced

by

gasotransmitters. In Chapter 4 we used the natural affinity of thiols and thioethers
towards gold nanoparticles in order to purify sulfur-containing tryptic peptides for mass
spectrometric analysis. Since cysteine residues are common targets of gasotransmitters
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NO and H2S, this technique could be used for studying post-translational modifications of
proteins induced by gasotransmitters.
Gasotransmitters like NO and H2S may also be used as therapeutic agents to treat
disease. For example, nitroglycerin is used to treat angina pectoris, and its activity is due
to the release of NO. Application of exogenous NO can improve cutaneous wound
healing, and there is a possible therapeutic application of NO for treatment of chronic and
persistent wounds. In Chapter 5 we developed NO-releasing materials that could be used
as wound dressings to improve wound healing. Chitosan is a natural, biocompatible, and
biodegradable polymer, which has been previously used as a wound dressing. By
incorporating copper into chitosan films, chitosan films can generate NO from inorganic
nitrite, and S-nitrosothiols. Although further studies are required, copper-chitosan films
could be potentially used as NO-releasing wound dressing.
Our understanding of H2S signaling is a lot less complete than NO signaling.
While NO is well-established to be a major determinant of vascular tone, H2S signaling
could even be described as controversial. Although H2S and NO are similar, some unique
challenges exist when studying H2S. The lack of specific enzyme inhibitors, as well as
detection methods has been a major challenge in H2S research. H2S-producing enzymes,
CBS, CSE, CAT, and 3-MST catalyze many different reactions in addition to H2S
generation. It is difficult, but very important, to separate these functions from H2S-related
effects. H2S can oxidize to numerous different sulfur species, and react with other redox
signaling molecules, including NO. Determining which reactions occur physiologically
will aid our understanding of H2S, and even NO biochemistry. Going forward, the
development of improved methods to study H2S, and furthering our knowledge of H2S
chemistry would greatly improve our understanding of H2S signaling. When drawing
biological conclusions it is paramount to appreciate the chemistry of gasotransmitters, the
chemical tools used to study gasotransmitters, and consider the big picture.
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Appendix A

Figure A-1 MALDI-MS spectra of vasopressin treated with 1,000 fold (1 mM) NaSH
and labeled with iodoacetamide. m/z 1084 represents unmodified vasopressin, m/z 1117
represents unlabeled singly S-sulfurated vasopressin, m/z 1175 represents singly Ssulfurated and iodoacetamide labeled vasopressin, m/z 1232 represents singly Ssulfurated and doubly iodoacetamide labeled vasopressin, m/z 1264 represents doubly Ssulfurated and iodoacetamide labeled vasopressin.
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Figure A-2 GAPDH protein purification gel. Lane 1: protein ladder, lane 2: purified
GAPDH, lane 3: E. coli crude lysate. Image was taken using a desktop scanner.
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Figure A-3 C156S GAPDH protein purification gel. Lane 1: protein ladder, lane 2: crude
lysate, lane 3: column flow-through, lane 4: wash #1, lane 5: wash #2, lane 6: purified
GAPDH. Image was taken using a commercial gel imager.
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Figure A-4 Example plot of GAPDH enzyme activity. Conversion of NAD+ to NADH
was measured at 340 nm. The initial rate up to 42 s was used for calculations.
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Figure A-5 GAPDH enzyme inactivation by oxidized glutathione (GSSG).
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Figure A-6 Enzymatic activity of purified GAPDH (1 µg/mL) as a function of increasing
NaSH concentration. GAPDH was supplemented with NAD+ before treatment with
NaSH. The addition of NAD+ did not change the effect of NaSH on GAPDH activity.
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Figure A-7 MS/MS spectrum of GAPDH tryptic peptide (m/z 765.90) containing
carbamidomethylated Cys 247, sequenced from reduced GAPDH sample (no NaSH or PS
treatments).

Figure A-8 MS/MS spectrum of GAPDH tryptic peptide (m/z 781.89) containing Ssulfurated and carbamidomethylated Cys 247, sequenced from reduced and NaSH-treated
GAPDH sample.
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Figure A-9 MS/MS spectrum of GAPDH tryptic peptide (m/z 737.39) containing
unlabeled Cys 247, sequenced from GSSG-treated GAPDH sample (no NaSH or PS
treatments).

Figure A-10 MS/MS spectrum of GAPDH tryptic peptide (m/z 889.92) containing
glutathionylated Cys 247, sequenced from GSSG-treated GAPDH sample (no NaSH or
PS treatments).
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Figure A-11 MS/MS spectrum of GAPDH tryptic peptide (m/z 593.61) containing
glutathionylated Cys 247, sequenced from GSSG-treated GAPDH sample (no NaSH or
PS treatments).

Figure A-12 MS/MS spectrum of GAPDH tryptic peptide (m/z 888.95) containing
carbamidomethylated Cys 152 and free Cys 156, sequenced from GSSG and NaSHtreated GAPDH sample.
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Figure A-13 MS/MS spectrum of GAPDH tryptic peptide (m/z 799.91) containing NEMlabeled Cys 247, indicating S-nitrosation of Cys 247, sequenced from GSNO-treated
GAPDH sample subject to differential labeling.

Figure A-14 MS/MS spectrum of GAPDH tryptic peptide (m/z 951.48) containing
carbamidomethylated Cys 152 and NEM-labeled Cys 156, indicating S-nitrosation of Cys
156, sequenced from GSNO-treated GAPDH sample subject to differential labeling.
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Figure A-15 MS/MS spectrum of GAPDH tryptic peptide (m/z 985.49) containing NEMlabeled Cys 152 and NEM-labeled Cys 156, indicating S-nitrosation of Cys 152 and Cys
156, sequenced from GSNO-treated GAPDH sample subject to differential labeling.

Figure A-16 MS/MS spectrum of C156S GAPDH tryptic peptide (m/z 852.45)
containing free Cys 152, sequenced from C156S GAPDH sample (no NaSH or PS
treatments).
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Figure A-17 MS/MS spectrum of C156S GAPDH tryptic peptide (m/z 880.96)
containing carbamidomethylated Cys 152, sequenced from C156S GAPDH sample (no
NaSH or PS treatments).

Figure A-18 MS/MS spectrum of C156S GAPDH tryptic peptide (m/z 896.95)
containing S-sulfurated and carbamidomethylated Cys 152, sequenced from PS-treated
C156S GAPDH sample.
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Appendix B

Figure B-1 PSD-MS spectrum of YVH1 peptide (m/z 937.96) from a 5 protein mixture
enriched for sulfur-containing peptides by AuNPs.

Figure B-2 PSD-MS spectrum of YVH1 peptide (m/z 966.36) from a 5 protein mixture
enriched for sulfur-containing peptides by AuNPs.
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Figure B-3 PSD-MS spectrum of YVH1 peptide (m/z 1183.16) from a 5 protein mixture
enriched for sulfur-containing peptides by AuNPs.

Figure B-4 PSD-MS spectrum of YVH1 peptide (m/z 1283.31) from a 5 protein mixture
enriched for sulfur-containing peptides by AuNPs.
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Figure B-5 PSD-MS spectrum of lysozyme peptide (m/z 1436.16) from a 5 protein
mixture enriched for sulfur-containing peptides by AuNPs.

Figure B-6 PSD-MS spectrum of PDI peptide (m/z 1537.41) from a 5 protein mixture
enriched for sulfur-containing peptides by AuNPs.
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Figure B-7 PSD-MS spectrum of lysozyme peptide (m/z 1677.65) from a 5 protein
mixture enriched for sulfur-containing peptides by AuNPs.

Figure B-8 PSD-MS spectrum of YVH1 peptide (m/z 1708.41) from a 5 protein mixture
enriched for sulfur-containing peptides by AuNPs.
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Figure B-9 PSD-MS spectrum of lysozyme peptide (m/z 1805.44) from a 5 protein
mixture enriched for sulfur-containing peptides by AuNPs.

Figure B-10 PSD-MS spectrum of BSA peptide (m/z 1825.68) from a 5 protein mixture
enriched for sulfur-containing peptides by AuNPs.
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Figure B-11 PSD-MS spectrum of PDI peptide (m/z 2419.85) from a 5 protein mixture
enriched for sulfur-containing peptides by AuNPs.

Figure B-12 PSD-MS spectrum of YVH1 peptide (m/z 2536.71) from a 5 protein
mixture enriched for sulfur-containing peptides by AuNPs.
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Figure B-13 PSD-MS spectrum of CSE peptide (m/z 2563.19) from a 5 protein mixture
enriched for sulfur-containing peptides by AuNPs.
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